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Abstract
Individuals with posttraumatic stress, anxiety and depressive disorders are currently being
prescribed medical marijuana as a treatment in many states across the United States. However,
marijuana is still considered a schedule one narcotic by the Drug Enforcement Administration
and federal government, which provides several barriers and challenges to conduct research such
as approval from the U.S. Food and Drug Administration and following guidelines from the
National Institute on Drug Abuse issued by the DEA. Additionally, individuals prescribed
medical marijuana for mental health disorders are not always thoroughly instructed on the type
of medical marijuana, the dosage, and how frequently to use marijuana. This literature review’s
objective was to understand what mental health symptoms medical marijuana treats and what
factors indicate medical marijuana is a suitable treatment for posttraumatic stress disorder,
anxiety, and depression. Cannabidiol and tetrahydrocannabinol have been found to contribute to
an acute reduction in both posttraumatic stress disorder and anxiety symptoms, although longterm efficacy is still unclear. Results have varied with depressive disorders regarding the
successful reduction of depressive symptoms. Conversely, studies have shown that medical
marijuana and recreational marijuana use may exacerbate depressive symptoms and psychosis,
and tetrahydrocannabinol-based medical marijuana products may not be best suited for
individuals with a history of substance abuse due to potential habit-forming qualities. In addition,
medical marijuana can have an impact on the concentration of psychotropic medications. Studies
to date have indicated that medical marijuana’s effective dosage for treatment may differ across
individuals depending on the disorder, individual factors, prior marijuana use, and time relative
to experience symptoms.
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CHAPTER I: INTRODUCTION
Individuals who experience PTSD, anxiety, and depressive disorders are currently being
prescribed medical marijuana as a treatment (Abizaid, Merali, & Anisman, 2019). Medical
marijuana was first legalized in the United Stated in 1996 and since has been a controversial
topic on local, state, and federal levels (Bridgeman & Abazia, 2017). There is limited data
available indicating the best practices for prescribing medical marijuana based on patient
characteristics such as diagnosis, chronic health conditions, and contraindications that would
impact the effectiveness of medical marijuana. When an individual is prescribed medical
marijuana, they have access to a medical marijuana dispensary (PA.Gov., 2020). At a dispensary,
prescribed individuals can choose various cannabis options from edibles, vaporizing oils, and
flower bud. They also can choose different strains of cannabis, which are predominantly indica
and sativa or blends of the two. Beyond the route of administration and strain, individuals can
then choose tetrahydrocannabinol (THC) or cannabidiol (CBD) products that also have different
levels of blends and can also be administered individually (PA.Gov., 2020). As a consumer, it
can be confusing what medical marijuana product may be right for them. Ideally, the doctor
prescribing marijuana will help their patients navigate the challenges of finding the right product.
History of Medical Marijuana
“Cannabis genus” are flowering plants derivative from Central America, which humans
have consumed for about 5,000 years (Hudak, 2016). There are three major cannabis species,
sativa, indica, and ruderalis, and they have different chemical characteristics, uses, and look.
Indica and sativa are common in cannabis production due to the high THC concentration in
recreational and medical marijuana. Sativa is typically associated with feelings of euphoria, and
indica is typically associated with the feeling of relaxation. Flower and particularly the bud are
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common names for the highest concentration of chemicals that influence the brain. “Bud”
delivered the ability to smoke the marijuana. Cannabinoids are a different part of the plant and
contain some of the same chemical components as the flower and bud. The whole plant is used
for commercial production to extract cannabinoids (Hudak, 2016). Cannabinoids can be
psychoactive or non-psychoactive. THC is responsible for the psychoactive and euphoric
responses associated with marijuana. CBD is typically associated with medical marijuana rather
than recreational use. CBD has many therapeutic uses, such as anti-seizure and antiinflammatory treatment. Medical marijuana has multiple delivery methods such as ointments,
creams, lip balms, salves, massage oils, moisturizers, and hundreds more (Hudak, 2016).
Regulation of Marijuana in America
In 1906, Congress passed the Federal Food and Drug Act (currently Food and Drug
Administration, FDA), which allowed the government to regulate and standardized commercial
drugs, foods, and other products (Hudak, 2016). Robins (1995) indicated that in 1914 the
Harrison Act was passed, and the United States made psychoactive drugs including marijuana
illegal, and thus they were only made available by a prescribing physician. During the 1930s,
Mexican immigrants crossing the border into the U.S. were deemed criminals with stereotypes
that associate Mexicans with “marihuana” (Hudak, 2016). In 1937, Congress passed the
Marihuana Tax Act, which was the first formal use of the word marihuana from the government.
The law required individuals who import, manufacture, produce, compound, sell, dispense,
prescribe, administer, or give away marijuana to register with the government (Hudak, 2016).
The Controlled Substances Act was passed in 1970 to reduce abuse of drugs, and marijuana
(THC) was categorized in the same was in the same class of drugs such as heroin, LSD, and
ecstasy (El-Zein, 2017). El-Zein (2017) indicated that since the first state legalized marijuana in
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1996 there has been a discrepancy between state and federal law. State law may permit
recreational and medical marijuana use, and federal law states marijuana is an illegal substance.
Possession of marijuana can result in a range of penalties from fines and imprisonment (El-Zein,
2017). The Drug Enforcement Administration (DEA) still considers marijuana a schedule one
narcotic, which is defined as substances with no currently accepted medical use and a high
potential for abuse (Drug scheduling, 2019).
Decriminalization and Legal Use of Marijuana and Medical Marijuana
Fichtner and Moss (2017) indicated that in 1985 THC was approved to treat vomiting and
nausea for individuals receiving chemotherapy, which was the first time the U.S. government
acknowledged potential therapeutic purposes for medical marijuana. California became the first
state to have medical cannabis laws and medical cannabis for commercial use in 1996. There are
several forms of medical marijuana, for example Sativex is an herbal extract with a THC:CBD
ratio of 1:1 and was the first cannabis product to gain medical approval for multiple sclerosis in
2005 and for chronic cancer pain in 2006 (Fichtner & Moss, 2017).
Currently, 16 states have fully legalized marijuana use for medical and recreational use:
California, Washington, Oregon, Nevada, Arizona, Colorado, Alaska, Michigan, Montana, South
Dakota, Vermont, Maine, Massachusetts, New Jersey, and Illinois. Washington D.C. also has
passed recreational marijuana use. Thirteen states have approved medical marijuana use but not
decriminalized recreational use: Arkansas, Florida, Georgia, Indiana, Iowa, Kentucky, Louisiana,
Oklahoma, Pennsylvania, Texas, Utah, West Virginia, Wisconsin. Of these, Georgia, Indiana,
Iowa, Kentucky, Texas, and Wisconsin are only approved for CBD use. Fifteen states have
approved medicinal use and decriminalization of marijuana: Connecticut, Delaware, Hawaii,
Maryland, Minnesota, Mississippi, Missouri, New Hampshire, New Mexico, New York, North

4
Carolina, North Dakota, Ohio, Rhode Island, and Virginia; however, Virginia is approved for
only CBD use. Two states have decriminalized recreational marijuana and but have not approved
medical use of marijuana: Nebraska and South Dakota. Seven states have medical and
recreational marijuana use designated as illegal: Idaho, Wyoming, Kansas, Tennessee, Alabama,
and South Carolina (“Map of marijuana legality by state,” 2021).
Medical Marijuana Treatment for Mental Health
Medical marijuana has been utilized by the medical profession to assist with ailments
such as multiple sclerosis, seizures, and chemotherapy’s harmful side effects (Bridgeman &
Abazia, 2017). However, recreational marijuana is viewed differently from state to state. Many
states are attempting to incorporate laws that decriminalize possession of marijuana, but conflicts
persist between federal and state law (El-Zein, 2017). THC is a phytocannabinoid (cannabinoids
that occur naturally in the cannabis plant) that can produce euphoric qualities in the consumers,
but the disadvantages are that it has a potential habit-forming risk with continual use (Ligresti et
al., 2016). Elms et al. (2019) conveyed that CBD is a phytocannabinoid and is viewed as an
anxiolytic that can help reduce anxiety and hyperarousal and is a non-psychotomimetic (does not
cause psychosis) cannabinoid compound. Elms et al. utilized a retrospective case study of 11
adult outpatient clients and examined the effect that oral CBD had on their PTSD symptoms over
an eight-week duration. The 11 patients were also treated with psychiatric medications and
psychotherapy and their symptoms were measured by PTSD Checklist for the DSM-5 (PCL-5;
Weathers et al., 2013). A total of 10 out of the 11 patients showed a decrease in PTSD symptoms
indicated by a reduction in their PCL-5 scores. Elms et al. concluded that oral CBD in
combination with psychiatric care has shown reduction in PTSD symptoms such as reduction in
nightmares. CBD has also shown promise in reducing anxiety and treatment for PTSD, although
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not proven at this point (Elms et al., 2019). Elms et al. have found significant results in their
research although limitations include a small sample size, and thus additional research is needed
to understand CBD’s impact on PTSD symptoms.
Feingold et al. (2017) indicated that medical marijuana use has been shown to reduce
anxiety and depression for patients with chronic pain compared to patients’ prescription opioids.
Feingold et al. examined 329 chronic pain patients prescribed medical marijuana compared to
474 chronic pain patients prescribed prescription opioids, 77 of whom were prescribed both.
Patients were assessed for depression using the Patient Health Questionnaire (PHQ-9; Kroenke
& Spitzer, 2001), and anxiety was screened using the Generalized Anxiety Disorder
questionnaire (GAD-7; Spitzer et al., 2006). Depression and anxiety rates were highest among
patients prescribed opioids compared to patients prescribed medical marijuana. Patients
prescribed both medical marijuana and opioids were more likely to report depression compared
to the medical marijuana group (Feingold et al., 2017). Limitations of this study include that the
research was cross-sectional, which reduces the chances of causality because only correlations
can be inferred from cross sectional data, and there are no variables that were manipulated.
Kosiba et al. (2019) conducted a systematic review and meta-analysis of empirical
studies that included medical marijuana treatment for patient-reported symptoms of pain,
anxiety, and depression. Kosiba et al. screened 2131 studies, which resulted in 109 full texts that
were reviewed. Thirteen of the full text articles that only incorporated self-reported reasons for
using medical cannabis were used, which included 6,759 participants from the thirteen selfreport articles. Kosiba et al. reported that 50% of medical marijuana patients reported that they
use it for anxiety, and 34% reported medical marijuana use for depression. The researchers
several found methodological limitations in the studies. Patient recruitment was a limitation
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because medical cannabis was only approved for certain medical conditions and may have
influenced the patients to endorse medical marijuana use for approved conditions, which may not
be the true reason for their use. Kosiba et al. highlighted Hawaii as an example of a state in
which pain is the only condition legally approved for medical cannabis, which may have reduced
the chances of an individual reporting medical cannabis use for reasons other than pain.
Restrictive sampling was another limitation due to convenience sampling, which can be biased
representations of a population. The last major limitation was the lack of randomized methods,
which may overestimate the benefit of medical marijuana (Kosiba et al., 2019).
Piper et al. (2017) presented data from a New England dispensary that held an online
survey about medical history and medical cannabis use. Piper et al. stated medical marijuana has
shown a “substitution effect” for opioids for managing pain, and they hypothesized that there is
an interaction between the cannabinoid and opioid neurotransmitter systems. The aim of the data
examination was to explore whether the substitution effect of medical cannabis for opioids had
similar result when substituting medical cannabis for psychoactive medications. There was a
total of 1,513 participants in the online survey. Among the 308 patients who used anti-anxiety
medication, 71.8% reported that they reduced their use of anti-anxiety medication, and 37.6% of
the 237 patients using antidepressant medication reported that they reduced the number of
antidepressants used after using medical marijuana. The substation effect for medical marijuana
has not been extensively studied and is typically associated with a substitution for pain
management (Piper et al., 2017).
Brain Anatomy and Neurotransmitters Involved in Medical Marijuana
There are several anatomical aspects of the brain to highlight in order to understand how
medical marijuana impacts mental health. Fogaça et al. (2014) reported that the prelimbic medial
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prefrontal cortex is a brain structure that influences the expression of emotional states, and
5HT1A is a serotonin receptor in presynaptic and postsynaptic neurons found in the prelimbic
medial prefrontal cortex. Activation of 5HT1A may provide anxiolytic and antidepressant
effects, and CBD is considered an agonist to the 5HT1A receptor. The activation of the 5HT1A
receptor by CBD may have similar actions as anxiolytic, antipsychotic, and antidepressant
medications (Fogaça et al., 2014).
The next anatomical structure of focus is the endocannabinoid system (eCB). Hill et al.
(2013) indicated that the endocannabinoid system (eCB) is composed of a central CB1 receptor
and two endogenous ligands, which serve as a means to activate the cannabinoid receptor (Narachidonylethanolamine [anandamide; AEA] and 2-arachidonoylglycerol [2-AG]). There are
also CB2 receptors, the expression of which is primarily restricted to immune cells of
macrophage lineage but may also be expressed in the central nervous system (CNS). The eCB
system is believed to constrain activation of the stress response through distributed actions in
limbic and hypothalamic circuits in the brain. The eCB system is responsive to glucocorticoids,
which regulate physiological actions of these hormones such as modulation of emotional and
cognitive processes. The eCB system is involved in extinction of negative emotional memories,
habituation, and adaptation to stress. Hill et al. believed that reduction in circulating
concentrations of eCB increase the likelihood of stress vulnerability. PTSD may be a result of
low concentrations of eCB signaling, which can help explain the reason some individuals are
more likely to develop PTSD symptoms after an event (Hill et al., 2013). Zhang and Ho (2015)
conveyed that CB1 receptors are most populated in the hippocampus, cortex basal ganglia, spinal
cord, and cerebellum, and CB2 receptors have the highest concentration in cells responsible for
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immune mediation, which helps to illuminate benefits and side effects of cannabis use (Zhang &
Ho, 2015).
Potential Physical Side Effects of Medical Marijuana
Medical marijuana that contains THC or CBD may have impacts on various medications
and may produce a number of side effects. For example, THC can have side effects such as
headaches, nausea, hallucinations, increased heart rate, increased appetite, fatigue, drowsiness,
dry mouth, red eyes, and dizziness (Mayo Clinic, 2020). THC may decrease concentrations of
various medications including clozapine, duloxetine, naproxen, cyclobenzaprine, olanzapine,
haloperidol, and chlorpromazine. CBD may increase concentrations of various pharmaceutics
including macrolides, calcium channel blockers, benzodiazepines, cyclosporine, sildenafil,
antihistamines, haloperidol, and antiretrovirals. CBD may also increase concentrations of various
medications including SSRIs, tricyclic antidepressants, antipsychotics, beta-blockers, and opioids
(Fugh-Berman et al., 2020).
Individuals who also experience psychosis and/or depression may be at risk of
exacerbating depressive symptoms, hallucinations, or psychosis when using nabilone, which is
synthetic THC used for the treatment of PTSD. Nabilone is a C1 receptor agonist spread
throughout the brain that has limited interaction with cardiorespiratory areas in the brain stem.
The implications of limited cardiorespiratory interaction reduce the risk of cardiorespiratory
suppression, which can be a concern with use of other treatments such as opioids (Cameron et al.
2014). When focusing on nabilone use with women who are pregnant, nabilone has not been
studied on women during pregnancy and has only been studied on pregnant animals, where it
was shown to increase embryo lethality, fetal resorptions, decreased fetal weight, and pregnancy
disruptions (U.S. FDA pregnancy category C). Therefore, when considering treatment for PTSD
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on pregnant women, the FDA does not recommend breastfeeding while on nabilone because
some cannabinoids are excreted in breast milk (Fugh-Berman et al., 2020).
Zhang and Ho (2015) conducted a review and reported that individuals who smoke
cannabis usually have the peak effect after 30 minutes after use, and the effects typically last for
2 to 4 hours. They found that cannabis use may potentiate anxiety or agitation, hallucinations,
paranoid ideations, impaired attention and judgment, and feelings of depersonalization.
Individuals who use edible marijuana may not experience the intensity of the above symptoms,
although high amounts of consumed marijuana can result in acute confusion, hypotension,
hypothermia, and experience of psychosis (Zhang & Ho, 2015).
Statement of Problem
Individuals with mental health diagnoses are starting to be prescribed marijuana as a
treatment. Prior to marijuana prescriptions, the treatment for mental health disorders primarily
consisted of antidepressants, antipsychotics, benzodiazepines, and psychotherapy. The
effectiveness of medical marijuana for individuals with mental health disorders and how it
compares with traditional medical and psychological interventions is unknown. Medical
marijuana may also have negative health ramifications and addiction potential. Although
marijuana has been approved for medical use in many states, there are conflicting perspectives
about whether medical marijuana should be used to treat mental health disorders. In addition, the
existing literature often does not specify or compare the same types of medical marijuana in the
available research, making it challenging to discern the efficacy. Finally, marijuana is still
considered a schedule one narcotic under federal law, which may complicate use in treatment as
well as broad based research on efficacy.
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Purpose of CRP Literature Review
The purpose of this literature review is to investigate medical marijuana treatment for the
symptoms of PTSD, anxiety, and depression. The review’s major goal is to provide clinicians
with an additional research tool to help inform psychotherapeutic interventions with individuals
who have been prescribed medical marijuana for PTSD, anxiety, and depression. This review
addressed the following research questions:
How may medical marijuana treat PTSD, anxiety, and depression?
What information supports and contraindicates medical marijuana as a suitable treatment
for PTSD, anxiety, and depression?
What are the client characteristics that make a good fit and characteristics that make a
client a poor fit for treatment with medical marijuana once diagnosed with PTSD, anxiety
disorders, and depressive disorders?
Research Procedure
Various databases such as Google Scholar, ProQuest, and EBSCOhost were utilized to
locate psychological and scientific journals and relevant information presented in books,
conference presentations, and dissertations that address medical marijuana, medical cannabis,
recreational marijuana, nabilone, CBD, and THC as a treatment for PTSD, anxiety disorders, and
depressive disorders. The research procedures were intended to identify patient characteristics
that would deem them advantageous or disadvantages in medical marijuana treatment, identify
health and legal barriers surrounding prescribing medical marijuana, and highlight the
interactions of medical marijuana and comorbid mental health disorders.
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CHAPTER II: RESEARCH FOR USING MEDICAL MARIJUANA TO TREAT PTSD,
ANXIETY, AND DEPRESSIVE DISORDERS
Supportive Research on Medical Cannabis for PTSD
PTSD is classified as a trauma and stressor-related disorder in the DSM-5. The
Diagnostic and Statistical Manual of Mental Disorders (5th ed.; American Psychiatric
Association, 2013) has seven criteria that must be met to receive a diagnosis of PTSD. Each of
the categories for PTSD has several criteria that help delineate a diagnosis. The following are the
diagnostic categories for PTSD: (a) exposure to actual or threatened death, serious injury, or
sexual violence; (b) presence of one (or more) of the following intrusion symptoms associated
with traumatic event(s); (c) persistence avoidance of stimuli associated with the traumatic
event(s), beginning after the traumatic event(s) occurred; (d) negative alterations in cognitions
and mood associated with the traumatic event(s) beginning or worsening after the traumatic
event(s) occurred; (e) marked alternation in arousal and reactivity associated with the traumatic
event(s), beginning or worsening after the traumatic event(s) occurred; (f) duration of the
disturbance (criteria b, c, d, and e) is more than a month; (g) disturbance causes significant
distress or impairment in social, occupational, or other important areas of functioning; and (h)
disturbance is not attributable to the physiological effects of a substance or another medical
condition (American Psychological Association, 2013).
LaFrance et al. (2020) conducted a study to understand the short- and long-term effects of
cannabis on symptoms of PTSD. The study was conducted over a 31-month period from March
2017 to October 2019. Data were acquired from a medical cannabis technology platform that
contains a journaling app and allows users to monitor changes in symptom severity and cannabis
use. Participants “self-identified” as having PTSD. The participants using the app can identify
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which mental health condition they are using cannabis to treat and provide their symptom
severity on a scale from 0 (no symptoms) to 10 (extreme experience of symptoms). The app
measures PTSD in terms of four components: intrusive thoughts, irritability, flashbacks, and
anxiety. The users also track their route of administration (e.g., smoke, vape, dab bubbler, dab
portable, oil, edible, pill, spray, transdermal, tincture). The users also indicated the strain of
cannabis and the producer/distributor, so the researchers then could obtain verified cannabinoid
content for each strain of cannabis. Only lab verified marijuana and inhaled method of
administration were included in the results for the LaFrance et al. study. Following use, the app
allows recording the dosage of marijuana (number of puffs) consumed, route of administration,
and measurement of PTSD symptoms. The participants are then provided a notification after a
period of 20 minutes to re-rate the severity of symptoms. This rating was recorded within 4 hours
of marijuana use for all participants (LaFrance et al., 2020).
LaFrance et al. (2020) chose 404 medical cannabis users (220 women, 176 men, and 8
other) who identified as having PTSD on the app. Symptom severity was measured prior to
marijuana use and 20 minutes after use (latent change score); this approach assisted in examining
changes in PTSD symptoms within subjects across time and allowed the researchers to compare
gender, dose, and cannabinoid content. The study found that irritability, anxiety, intrusive
thoughts, and flashbacks were significantly reduced after marijuana use. A high number of puffs
of cannabis was the strongest predictor of symptom relief for anxiety and intrusive thoughts.
Women reported higher rates of flashback severity reduction and anxiety reduction compared to
men. Men reported significantly higher rates of irritability reduction compared to women. The
results found no gender differences in intrusive thoughts. Overall, individuals with PTSD
reported a 62% reduction in intrusive thoughts, a 51% reduction in flashbacks, a 67% reduction
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in irritability, and a 57% reduction in anxiety when measured before and after inhaling cannabis.
Individuals with a higher severity of symptoms showed a larger reduction in symptom severity.
There was no significant difference in symptom changes when comparing THC to CBD. Thus,
cannabis use appeared to assist in temporary relief from PTSD symptoms. The results also
indicated that higher doses were used to manage anxiety, but individuals’ baseline PTSD
symptom ratings did not change over time (LaFrance et al., 2020). Thus, marijuana did not
appear to have an impact on the presence of PTSD symptoms and only served as acute relief
from PTSD symptoms. LaFrance et al. acknowledge that the implications of the results are that
marijuana may reduce PTSD symptoms in short-term and may not have long-term effectiveness
in sustained PTSD symptom reduction. There are a number of limitations of this study. The
research did not utilize confirmed PTSD diagnosis and relied on “self-identified” PTSD. The
research also did not use a validated measure of PTSD. Thus, all participants may not meet the
actual criteria for PTSD. LaFrance et al. did not utilize a randomized placebo control group,
which reduces the ability to make accurate predictions of the effectiveness of marijuana on
PTSD symptoms. The study was also conducted from voluntary participants on a journaling app,
which calls into question the reliability of the data. The strength of the study is based on utilizing
a quantitative longitudinal cohort study with a considerably large sample size of over 400
cannabis users, which allowed the researchers to analyze PTSD symptoms over a 31-month
period with multiple ratings for each participant. The 404 medical cannabis participants
produced 11,797 ratings within that 31-month period. Also, lab-verified cannabis was utilized,
which increased the control the researchers had to compare potency and concentration of THC
and CBD.
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Treatment for PTSD with THC
There has been a limited amount of research focusing on THC treatment for PTSD. In
order to compare studies explaining the effectiveness of THC treatment, this review focused on
the type of THC, the dosage, participants’ individual differences, route of administration, what
measures were utilized to track changes in symptoms, comorbid mental health disorders, and
identifying any other treatment being implemented during the time of THC treatment.
Roitman et al. (2014) conducted research to determine the use of orally absorbable THC
for chronic PTSD. The study was a 3-week preliminary evaluation of the safety, tolerance, and
efficacy of THC (Roitman et al., 2014). The study was considered “open label,” which means
that the participants and the researchers were aware of the drug (THC) being administered in the
study. The participants consisted of 10 adult individuals (7 male and 3 female) from a mental
health outpatient clinic in Jerusalem, Israel. Each participant had been diagnosed with PTSD for
at least 1 year it had been and at least 3 years or longer since they experienced their traumatic
event. Each participant was currently on psychotropic medication and continued the medication
throughout the trial. Each participant was taking an average of more than four different
psychotropic medications, including Duloxetine, Escitalopram, Mirtazapine, Bupropion,
Clonazepam, and Lorazepam. The researchers used the Clinicians-Administered PTSD Scale
(CAPS; Blake et al., 1995) to validate the PTSD diagnosis. CAPS is considered a structured
clinical interview that surveys the Diagnostic and Statistical Manual of Mental Disorders, fourth
edition (DSM-IV) criteria based on frequency and intensity on a 0-4 Likert scale. The CAPS
assisted the researchers in determining the presence or absence of PTSD, in which higher ratings
indicated increased levels of PTSD symptomology and severity. The researchers also utilized the
DSM-IV to confirm PTSD diagnosis. The Clinical Global Impression Scale (CGI; Guy, 1976)
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was utilized to measure the severity of illness and global improvement. The Pittsburgh Sleep
Quality Index (PSQI; Buysse et al., 1989) was utilized to quantify sleep disturbances and sleep
quality. The researchers also utilized the Nightmare Frequency Questionnaire (NFQ; Krakow et
al., 2002), which identified the frequency of the participants’ dreams. The Nightmare Effects
Survey (NES; Krakow et al., 2000) was implemented to examine work, relationships, sleep,
daytime energy, mood, school, sex life, mental health, diet, leisure activities, and physical health
and to determine the level of impairment accounted for by the participants’ nightmares (Roitman
et al., 2014).
Roitman et al. (2014) excluded individuals who displayed dissociative symptoms or
endorsed alcohol or drug abuse, individuals experiencing psychosis, and women who were
pregnant or nursing. Individuals were also excluded if they had used cannabis within the last 6
months; however, they allowed one patient who “reported such a condition” to participate in the
study. Neither the particular condition endorsed nor the reason why the participant was not
excluded was explained. Each participant underwent physiological measures such as heart rate
and blood pressure ratings and were assessed for body mass index at the beginning and
throughout the study (Roitman et al., 2014).
Roitman et al. (2014) administered 2.5 mg of THC beneath the tongue twice per day and
after two days they raised the dosage to 5mg of THC twice per day until the end of the 3-week
trial if the participants did not endorse adverse side effects. Roitman et al. found a statistically
significant decrease in PTSD hyperarousal symptoms, CGI, sleep quality, frequency of
nightmares, and total NES scores. Two participants reported they did not experience any
nightmares in the 3-week trial. As for side effects, two participants reported dry mouth, one
participant endorsed headaches, and one participant reported dizziness (Roitman et al., 2014).
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Roitman et al. (2014) concluded that oral THC did not cause harsh side effects and
viewed oral THC as relatively safe. The researchers noted that ingesting oral THC was
associated with improved sleep quality and reduced nightmares by reducing rapid eye movement
sleep and increasing non-REM phase 4 sleep, which appear to be consistent with Fraser’s (2000)
research. Roitman et al. indicate that their pilot study had a relatively small sample size, which
decreases the ability to generalize their findings. The researchers used a cross-sectional
quantitative design, which decreases the ability to analyze behavior over an extended period of
time and determine causality. The researchers acknowledged that the use of an open label design
that lacks randomized placebo-controlled trials makes determination of changes in PTSD
symptoms difficult to assign to oral THC use versus variability during the course of PTSD.
Therefore, oral THC cannot be determined to be the cause of the reduction in PTSD symptoms
and results are correlational at best. The researchers appeared to conduct a thorough assessment
of PTSD symptoms through five objective measures and utilizing the DSM-IV criteria, which
increases the likelihood of an accurate PTSD diagnosis.
Several researchers investigated the impact the endocannabinoid system has on emotional
learning. Greer et al. (2014) completed a statistical analysis of psychometric data for 80
psychiatric evaluations of individuals applying to New Mexico medical cannabis programs. The
Clinician-Administered Posttraumatic Scale for DSM-IV (CAPS; Blake et al., 1995) was utilized
to measure PTSD symptoms based on a retrospective chart review of symptoms. The CAPS
measures reexperiencing, avoidance, and arousal. Greer et al. used telephone screening to
determine who would move forward with an evaluation, and to exclude individuals who did not
meet the DSM-IV criteria for PTSD. Greer et al. also examined and included only individuals
who endorsed symptom reduction in PTSD symptoms while using cannabis, and presence of
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PTSD symptoms when not using cannabis. Greer asked patients to utilize the CAPS questions
during a time they were not using cannabis and also answer the same questions on the CAPS
during a time when they were using cannabis. Analysis determined that there was a significant
reduction in symptoms related to reexperiencing, avoidance, and hyperarousal for individuals
using cannabis compared to no cannabis use. Of cannabis users, 75% showed an overall
reduction in CAPS scores (Greer et al., 2014). However, there were several limitations in this
study. The researchers reported that they did not collect any information on the length of time
with or without cannabis use, which significantly reduces the validity for determining how
effective cannabis use is on reducing PTSD symptoms. Also, using a retrospective design and
having patients evaluate their symptoms with and without marijuana use raised questions
regarding how accurate individuals are at remembering the severity of their symptoms
potentially months or years after. The researchers also screened for individuals who endorsed
experiencing reduction in PTSD with the use of cannabis, which can increase the likelihood of
participants showing significant results in PTSD symptom reduction and therefore be less
representative of individuals with PTSD in general. Greer et al. utilized a within subject
correlational design that appeared to find statistically significant results although the
generalizability appeared low due to only evaluating patients who reported benefiting from
cannabis.
Treatment for PTSD with Nabilone
Cameron et al. (2014) conducted a retrospective study on the effects of nabilone (a
synthetic cannabinoid) on treating insomnia and nightmares related to PTSD symptoms.
Cameron et al. surveyed 104 males, with an average age of 32.7 years, who were inmates at a
dual correction center and mental health center for persistent and serious mental illness. On
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arrival, all inmates were screened for PTSD, sleep time, nightmares, and substance use.
Pretreatment and posttreatment sleep hours per night and nights with nightmares per week were
measured by the self-report Posttraumatic Checklist-Civilian version (PCL-C; Weathers et al.,
1994), and the Global Assessment of Functioning and PTSD criteria from the DSM-IV-TR (GAF;
Aas, 2011; DSM-IV-TR, American Psychological Association, 2000). Every inmate participated
in weekly psychiatric sessions that monitored symptomology (Cameron et al., 2014).
Cameron et al. (2014) reported that prior to incarceration, chronic pain, cannabis
dependence, and trauma were prevalent among inmates. The study involved a retrospective chart
review of inmates who had been prescribed nabilone over a 3 year and 7-month period. The
average initial dosage was 1.4 mg daily, and the average final dose was 4.0 mg daily, with the
average length of 11.2 weeks on nabilone. One hundred one inmates reported an increase in
average hours slept, and 90 inmates reported a reduction in nightmares experienced per week.
Sleep quality, sleep time, and reduction in nightmares were reported within the first 2 weeks of
treatment. Fifty-eight inmates who had “moderate” PTSD symptoms improved to “borderline
mild” PTSD symptoms based on their GAF score. One hundred three inmates reported
significant improvements in functioning on the GAF scale. With the initiation of starting
nabilone, 90 medications were discontinued (antidepressants, benzodiazepines, cyclopyrrolones,
antiadrenergic, methadone codeine, anticonvulsants, and prednisone) by various inmates due to
either an indication from the inmates that nabilone was an adequate substitute or when the
medications were found to be of limited efficacy. Antipsychotics, sedative hypnotics, and
opioids were stopped because of the risk of serious adverse effects or abuse. Ten inmates who
had preexisting psychotic disorders showed a reduction in PTSD symptoms with the use of
nabilone while remaining on their antipsychotic medications. Adverse effects were noted in a
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portion of the inmates as a result of nabilone treatment. Thirty-one inmates reported adverse
effects including dry mouth, feeling “stoned”, hypotension, agitation, and headache. Two
patients reportedly experienced psychosis; each had a preexisting psychotic illness. Twenty
inmates discontinued the nabilone trial, 10 of which were due to adverse effects, four due to
abuse of other medications, and two inmates were going to a treatment center that did not allow
for nabilone use. Inmates who had no cannabis experience appeared to experience a higher rate
of adverse effects, suggesting these individuals may require a lower initial dose to
counterbalance adverse effects (Cameron et al., 2014).
Overall, Cameron et al.’s (2014) research has shown reduction in PTSD related
nightmares and insomnia has shown that nabilone may help reduce the number of medications
needed to manage PTSD symptoms. Reducing the number of medications with the use of
nabilone may reduce the risks associated with taking multiple medications, but more research
would be needed to prove this phenomenon. The question of whether cannabis dependent
individuals may benefit is mentioned by Cameron et al., although there is no data from the study
that suggests that cannabis dependent individuals may benefit and in what way. The study has
several limitations. A retrospective chart review has several disadvantages such as relying on the
accuracy of previous records, which provides lack of control in the scoring and interpretation of
the assessments administered to the participants. The research is a within-subject design that can
allow observation of changes within the participants over time, in which Cameron et al. were
able to find significant results for the benefits of nabilone. In order to confirm their finding, a
randomized placebo-controlled studies would be necessary. Cameron et al.’s utilization of
inmates allows for certain control for environmental factors although how applicable their
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findings would translate to an uncontrolled environment and other non-forensic populations is
not able to be determined.
Additional research has found similar results regarding the positive effects nabilone had
on sleep issues related to PTSD. Jetly et al. (2015) conducted a study that involved the efficacy
of nabilone capsules on 10 Canadian male military personnel diagnosed with PTSD. The design
of the study was double blind placebo controlled, in which the men either received .5 mg of
nabilone orally or a placebo. The participants were administered the Clinical Global Impression
(CGI; Guy, 1976) and the Clinicians-Administered PTSD Scale (CAPS; Blake et al., 1995). Each
participant received nabilone or placebo for 7 weeks, and the doses were adjusted for nightmare
suppression to a level that they determined was an effective dose. The maximum dosage
administered to the men was 3.0 mg. The study found a significant reduction in nightmares when
comparing pre and post CAPS scores for both the nabilone and placebo groups, and a reduction
in frequency and intensity of nightmares for both the nabilone and placebo groups. The nabilone
group was found to have a larger decrease in nightmares, frequency, and intensity than the
placebo group. The improvement in CGI scores was similar to CAPS results in that improvement
was seen in both nabilone and placebo groups and the nabilone showed a larger improvement in
CGI scores. The nabilone group reportedly had five out of 10 participants in the “much
improved” range on their CGI scores (5 out of 10) compared to the placebo group, which had
one out of nine in the “much improved” range. (Jetly et al., 2015). Jetly et al. indicated that the
sample size of their study was small, and stated further exploration is needed to understand the
effect of nabilone. Jetly et al.’s study does utilize a double-blind placebo-controlled design, but
the study will need to be recreated on larger sample sizes to get closer to data that can link cause
and effect. The results also show reduction in nightmares measured by CAPS scores for both the
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placebo and nabilone group but does not provide a clear indicator that nabilone is the only factor
that is allowing for improvement in nightmare reduction. The nabilone group did show a larger
improvement in their CAPS, which may indicate that there are confounding variables that are a
factor in nightmare reduction.
The commonality among nabilone research studies appears to be the reduction of
nightmare frequency and intensity with individuals diagnosed with PTSD. Fraser (2009)
conducted a review on an open label clinical trial to evaluate the effect of nabilone on treatment
resistant nightmares for individuals diagnosed with PTSD. The 47 individuals who had PTSDrelated nightmares were recruited from a psychiatric specialist outpatient clinic between 2004
and 2006. The participants were required to experience at least one nightmare per week to be
eligible for the study. PTSD diagnosis was confirmed by the Posttraumatic Stress Diagnostic
Scale (Foa, Cashman, Jaycox, & Perry, 1997), and each participant had at least a 2-year history
of PTSD related nightmares. Each participant was classified as “treatment-resistant” to
antidepressants and hypnotic medications. However, current use of medication regiments was
continued during the study. Individuals with psychosis and sensitivity to cannabinoids were
excluded from the study. Dosage of nabilone started at 0.5 mg 1 hour before sleeping. Patients
were seen within 7 days of starting nabilone treatment to monitor side effects and to increase
dose if the nabilone was tolerated and nightmare symptoms were not decreasing. The participants
were seen weekly for monitoring and adjustments, and the participant’s dosage after adjustment
ranged from 0.2 mg to 4.0 mg. Of the participants, 72% reported a significant decrease in the
severity of nightmare symptoms or a complete remission of nightmares. Four participants
experienced sustained reduction or reduced intensity in nightmares 4 to 12 months after the
discontinuation of nabilone use compared to the 43 participants who had a resurgence of
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nightmares. Thirteen participants experienced side effects such as headache, lightheadedness,
forgetfulness, and dizziness that lead to discontinuation of nabilone (Fraser, 2009).
Fraser (2009) identified that a major limitation of the study was there was no control
group to measure effectiveness. Similarly, to Cameron et al. (2014), the study lacked a doubleblind placebo control design and instead incorporated a within-subject open labeled design that
cannot enhance the current knowledge to determine nabilone’s effectiveness for reducing and
eliminating nightmares. Fraser also indicated that the subjective reports of nightmare change and
the small number of patients was a disadvantage to the study due to a lack of objective measures
to track changes and reduced ability to generalize to larger groups. The last major limitation
Fraser discussed was selection bias because all of the patients who were referred had a diagnosis
of PTSD and experienced treatment resistant nightmares. On the one hand, this participant
selection method may potentially increase the understanding of nabilone’s effect on treatment
resistant nightmares. However, selecting a subgroup of individuals with PTSD may ignore the
effect nabilone may have on individuals with PTSD that do not experience treatment resistant
nightmares. Fraser’s results are consistent with Jetly et al. (2015) and Cameron et al. (2014) in
demonstrating PTSD related nightmare reduction with nabilone treatment. However, further
studies are necessary to determine the effectiveness of nabilone for other groups with symptoms
of PTSD or other individuals who experience nightmares.
Nabilone has been shown to have low indicators of abuse potential. Ware and St. ArnaudTrempe (2010) conducted a literature review of scientific literature, popular press, and internet
databases to investigate the abuse potential for nabilone from 2002 to 2006. Ware and St.
Arnaud-Trempe reported there has been little evidence for recreational use and abuse of nabilone
(Clark et al., 2005; Gourlay, 2005). Two studies that tested subjective effects in humans showed
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that a single dose of 1 to 5 mg of nabilone does not significantly alter mood state (Glass et al.,
1980) or serve as a reinforcer (Mendelson & Mello, 1984; Ware & St. Arnaud-Trempe, 2010).
Treatment for PTSD with CBD
CBD treatment has not been extensively researched for various mental health concerns,
including PTSD. However, in a related study, Das et al. (2013) attempted to evaluate CBD’s
effect on fear extinction in humans, using a “Pavlovian fear-conditioning paradigm.” Das et al.
examined whether CBD could aid in the treatment of fear memories. Das et al. utilized a doubleblind, placebo-controlled between-subjects design. Participants were recruited by community
advertisements and word of mouth. The inclusion criteria required an age of 18-35 years old,
fluency in English, no history of serious mental or physical health problems, no substance abuse,
normal color vision, no learning impairment or neurological impairment history, and the
participant could not be pregnant. Forty-eight participants were randomly assigned to three
groups: 32 mg of inhaled CBD prior to extinction (pre-extinction group), 32 mg of inhaled CBD
following extinction (post-extinction group), and inhaled placebo ethanol, which were all
vaporized at 210 degrees C. (Das et al., 2013).
The pre-extinction group received 32 mg of inhaled CBD and each member of the other
two groups received a placebo 5 minutes prior to the fear extinction task (Das et al., 2013). The
post-extinction group received 32 mg of inhaled CBD and the other two groups inhaled a
placebo after the fear extinction task. The fear conditioning included a computer monitor called
“Room A,” which incorporated an image of a white wall. The unconditioned stimulus (UCS) was
an electric shock (250-ms; 4-mA electric shock). The conditioned stimuli (CS) were red and
yellow boxes that would appear in the background. One box (CS+) was paired with the shock,
and the other box (CS-) was never paired with the shock. Thirty-two conditioning trials either
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elicited a shock (CS+) or no shock (CS-), and skin conductance response was measured through
silver chloride electrodes attached to the middle finger of the participants. Explicit learning was
measured by shock expectancy ratings from 0 to 5; the higher the number, the more certain there
would be a shock (Das et al., 2013).
In “Room B” the fear extinction consisted of the same process as Room A but with no
shocks. The fear recall task was administered 34 hours later and had 2 phases (recall and
reinstatement). Recall consisted of presenting the CSs from the conditioning and extinction trials.
The recall contexts were presented in an alternating fashion, with each CS appearing in each
context before context change. The reinstatement phase was almost exactly like the recall phase
but was preceded by a single UCS presentation in each context to reactivate contextual fear
memory. The results showed a significant conditioning effect of the CS in the second and first
block based on the measurements from the skin conductive response. Decrease in skin
conductive responses happened during the course the trials was believed to be due to habituation
of the UCS. Extinction was reportedly evidenced by a significant decrease in skin conductive
responses between the last block of conditioning and all extinction blocks, and between the first
and later blocks of extinction trials. Das et al. found that CBD administered after extinction
learning led to a reduced impact of explicit fearful responding during recall and reinstatement.
Das et al. concluded that CBD could increase consolidation of extinction learning (Das et al.,
2013). Specifically, Das et al. proposed that their findings suggest sub-anxiolytic dose of CBD
given post-extinction increased the consolidation of extinction learned by reducing the UCS
expectancy, which may have implications of reducing fear for individuals who have a fear
response to an item, situation, or person.
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However, the applicability to PTSD and reducing the association of a trauma response
towards a conditioned stimulus created through trauma is not directly evidenced in this study.
The double-blind, placebo-controlled between-subjects design study provided control to examine
the effects of CBD administered before and after electric shocks to determine whether fear
expectancy has changed in individuals without PTSD. However, the same claims cannot be
generalized to individuals with PTSD due to the nature of the disorder and the design of the
study. It is not clear who will develop PTSD following a traumatic event or repeated exposure to
trauma. The expectancy of a low-level electric shock can cause an association of fear through
conditioning. However, it is not entirely comparable to the association between the strength of
association between trauma and fears associated responses for individuals with PTSD. The study
may provide insight on how CBD use effects conditioning, extinction, and recall in a controlled
environment but does not provide evidence to support the conclusion that same effect may take
place in extinction of PTSD related memories and associations.
Additional research has also supported the idea that CBD may be effective in treating
PTSD by reducing nightmares and other associated symptoms. Elms et al. (2019) conducted a
retrospective case study to determine CBD effectiveness as a treatment for PTSD with
participants from a mental health clinic. CBD (in capsule and liquid spray form) was
administered to 11 adult patients diagnosed with PTSD. Eight patients were female and three
were males. Eight patients were receiving psychotherapy, and each patient was taking at least
one medication, which included antidepressants, mood stabilizers, anxiolytics, and stimulants.
Comorbid mental disorders and cannabis use were not exclusion criteria. The patients also
received various treatments such as medications and psychotherapy. Four patients received oral
CBD, one patient received oral liquid spray CBD, and six patients received both liquid spray
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CBD and oral CBD. The oral CBD capsules contained 22-28 mg of CBD. The liquid spray CBD
contained 1.5 mg per spray, with the average dose per day being 9 mg. Each participant took
CBD twice per day. Each patient’s symptoms were measured once at 4 weeks and after 8 weeks
by patient completed PTSD Checklist for the DSM-5 (PCL-5; Weathers et al., 2013). The
average starting dose for either the liquid spray or the capsule was 33.18 mg. At the conclusion
of the study, the average dose was 48.64 mg. Increase in CBD dosage appeared to have the most
impact on the reduction of PTSD symptoms. At week 4, 10 of the 11 patients reported a decrease
in the symptoms of PTSD according to their PCL-5, with 1 patient experiencing an increase in
PTSD symptoms. After 8 weeks, eight patients reported a decrease in PTSD symptoms from
their results at 4 weeks. Three patients reported an increase in PTSD symptoms at eight weeks
compared to their results at four weeks. CBD use was shown to decrease both frequency and
intensity appeared to have the largest decrease in PTSD symptoms (Elms et al., 2019).
Elms et al.’s (2019) conducted a retrospective case study, which has similar concerns to
Cameron et al. (2014) and Fraser (2009) studies in that it did not incorporate a double-blind
placebo control design and instead utilized a within-subject open labeled design that can only
provide correlational data that cannot determine causation. Therefore, the study does not provide
data that CBD is the reason for the reduction in PTSD related symptoms. CBD was also
administered in oral and liquid spray, and the impact of different routes of administration was
unknown. The study does suggest decreased PTSD symptoms when considering the decrease in
PCL-5 scores, but future controlled studies are needed to confirm whether CBD truly reduces
PTSD symptoms.
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Inconclusive or Unsupportive Research for use of Medical Marijuana for PTSD Treatment
Johnson et al. (2016) conducted a matched case-control cross-sectional study with
veterans to understand the association between cannabis use and PTSD symptoms from January
2011 to December 2014. The veterans in the study were classified as veterans with probable
PTSD. Seven hundred patients were classified in two groups, “cannabis users” (N = 350) or
“non-users” (N = 350), and the non-users were used as a control group. The PTSD ChecklistCivilian version (PCL-C; Weathers et al., 1994) was utilized to measure the impact of cannabis
on PTSD symptoms. The participants were also administered two questions related to alcohol
from the Substance Involvement Screening Test (ASSIST; Ali et al., 2002), and the Patient
Health Questionnaire (PHQ-9; Kroenke & Spitzer, 2001) was used to assess for depression, and
Paykel Questionnaire (PQ; Paykel et al., 1974) was used to assess for suicidal ideation. Johnson
et al. did not find significant difference in PCL-C scores between cannabis users and non-users.
Frequency of cannabis use in the cannabis use group did not appear to have an impact on PCL-C
scores. Cannabis users appeared to have greater levels of alcohol consumption and suicidal
ideation compared to non-users (Johnson et al., 2016).
Johnson et al. (2016) proposed that their results suggest cannabis use is not associated
with PTSD symptom reduction. A major concern with that conclusion is that they are assuming
that PTSD severity did not differ between users and non-users. However, the veterans did not
appear to have a definite diagnosis of PTSD and were considered to have “probable PTSD”.
Therefore, conclusions on whether cannabis has an impact on PTSD can only be generalized to
PCL-5 score consistency within a case-match design. Johnson et al. stated that a limitation to
their study was the sample is a convenience sample of veterans being referred for clinical
assessments and thus sampling bias may limit generalizability to veterans who are not seeking
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treatment. Another limitation was the data available for the cannabis that is being used. The
cannabis was not designated as medical or recreational, dosage was not included, nor was the
route of administration. The study also did not control for prior or current treatment with
therapeutic interventions or psychotropic medication. Finally, the conclusions from this study are
correlational, which makes it difficult to determine how applicable their results are to cannabis
use and the impact it has on PTSD symptoms, particularly due to the design that compares users
and non-users without within-subject repeated measures over time.
Brown University (2017) conducted a systematic review of cannabis treatment for PTSD
and chronic pain, which was inconclusive due to the lack of well-designed studies on cannabis’
effects and insufficient evidence presented within the available studies. The review included a
“comprehensive search” of data published to March 2017 that included use of cannabis treatment
for PTSD, which included plant-based cannabis preparations or whole-plant extracts but
synthetic cannabinoids were not included. The review yielded two systematic reviews. One of
the systematic reviews focused on six studies. Of those six studies, two were prospective, open
label trails with no control group and one was a case study. The other systematic review included
four observational studies. Three of the studies reported that cannabis was associated with
reduction in PTSD symptoms and the remaining fourth observational study stated that cannabis
was associated with increase in PTSD symptoms (Brown University, 2017). There are several
limitations to the conclusions of this review. The review focused on general cannabis use and not
medical cannabis and also excluded synthetic cannabinoids, which have shown promise in PTSD
symptom reduction. The focus on cannabis in general as opposed to focusing on medical
marijuana may explain the inconclusive results. The review also stated that there are a lack of
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well-designed studies and that the evidence is too limited to determine if cannabis can be a
treatment for PTSD or potentially cause more harm.
Metrik et al. (2018) conducted a study to compare medical cannabis users with
recreational cannabis users. Researchers utilized data from an ongoing prospective study on
cannabis use and affective disorders in returning veterans deployed post 9/11. The study
identified 143 participants who endorsed cannabis use in the past year, and 93% of the
participants were male. The participants were administered the Medical Marijuana Patient
Questionnaire (MMPQ; Cohen, Heinz, Ilgen, & Bonn-Miller, 2016) and were classified as
“medicinal cannabis” users if they reported ever using cannabis for medical purposes on the
MMPQ. Sixty-six participants were identified as medical cannabis users if they endorsed ever
using cannabis for medical purposes and 25% of these participants reported having a state-issued
medical marijuana card. The medicinal cannabis users were then administered the Reasons for
Medical Marijuana Questionnaire (RFUMM; Reinarman, Nunberg, Lanthier, & Heddleston,
2011) to determine how often they used medical marijuana and the reason why. Seventy-seven
participants were identified as recreational users if they did not endorse using marijuana for
medicinal purposes on the MMPQ. The Clinician-Administered PTSD Scale for Diagnostic and
Statistical Manual of Mental Disorders (DSM-IV; CAPS; Blake et al., 1995) was administered to
both medicinal users and recreational users to assess for PTSD symptoms. Structured Clinical
Interview for DSM nonpatient edition (SCID-NP; First, Spitzer, Gibbon, & Williams, 2002) was
used to determine the past-month and lifetime diagnosis. The Time-Line Follow-Back (TLFB;
Dennis et al., 2004; Sobell & Sobell, 1992) is a structured interview that was used to determine
the frequency and quantity of cannabis consumed within the past 6 months. The TLFB also
assessed the frequency and quantity of alcohol consumption and other drug use. Marijuana
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Problems Scale (MPS; Stephens, Roffman, & Curtin, 2000) was administered to assess cannabis
related problems in the past 90 days. The Comprehensive Marijuana Motives Questionnaire
(CMMQ; Lee, Neighbors, Hendershot, & Grossbard, 2009) was administered to evaluate how
often the participants used cannabis and the reason for cannabis use. The Pittsburgh Sleep
Quality Index (PSQI; Buysse, Reynolds, Monk, Berman, & Kupfer, 1989) was also utilized to
assess for sleep quality and sleep disturbances over a 1-month period. The RAND (SF-36; Hays
& Morales, 2001) was utilized as a health-related quality of life measure of physical and mental
health. The Perceived Stress Scale (PSS; Cohen, Kamarck, & Mermelstein, 1983) was used to
measure the participant’s perception of life stress and the Satisfaction with Life Scale (SWLS;
Diener, Emmons, Larsen, & Griffin, 1985) was also used to measure the participants’ judgments
of their life satisfaction (Metrik et al., 2018).
Metrik et al. (2018) found that medicinal cannabis users reported using marijuana for
anxiety, stress, PTSD, pain, depression, and insomnia. The RFUMM results indicated that
medicinal users’ most frequent reason for use was to improve sleep and relaxation, with the
second most frequent reason for use to relieve PTSD. Metrik et al. also found that medicinal
users were five times more likely than recreational users to have a current diagnosis of PTSD and
four times more likely to have a current diagnosis of major depressive disorder. The results for
cannabis use motives indicated that medicinal users reported using cannabis more frequently
than recreational users for enjoyment, coping, social anxiety, and sleep. Medicinal users also had
indicators of worse sleep qualities compared to recreational use on their PSQI scores and also
had lower scores on their SF-36 (Metrik et al., 2018).
Metrik et al.’s (2018) strengths of the study are that it was a cross-sectional between
group quantitative research design that utilized several objective measures to make comparisons
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between recreational cannabis users and medicinal cannabis users. The results indicated that
medicinal users were more likely to have a current diagnosis of PTSD and MDD. These mental
health concerns may explain the reason medicinal users consume cannabis and the increased
frequency and quantity of cannabis used compared to recreational users. The study did not
provide information whether cannabis use is benefitting the medicinal or recreational user, which
would require more data and measures over time. Metrik et al. also identified the limitation that
their findings cannot be generalized to women due to the low number of women involved in the
study. Another limitation that was endorsed was the inability of the study to determine a
relationship between cannabis use and increase or decrease in symptoms regardless of whether
participants were a medicinal user or recreational user. Metrik et al. proposed that planned
longitudinal analysis is needed to determine the relationship between the variables in question.
Supportive Research on Medical Cannabis for Anxiety Disorders
There are indicators that suggest medical cannabis use can reduce symptoms in anxiety
disorders. The Diagnostic and Statistical Manual of Mental Disorders (5th ed.; American
Psychiatric Association, 2013) has several disorders in the anxiety category. Common symptoms
of these disorders include feelings of nervousness and/or excessive fear, restlessness, fatigued,
difficulty with concentration, and irritability. Anxiety disorders can also be accompanied by
physiological systems such as palpitations, sweating, chest pain, feeling dizzy, numbness, and
heat sensations. The endocannabinoid system has been shown to have an interaction with
anxiety. Alger (2014) wrote about how the endocannabinoid system plays a role in cell signaling
and is involved in regulating mood, appetite, learning, memory, reproduction, and fertility. The
central nervous system (CNS) contains the bulk of cannabinoid receptors (CB1), and CB2
receptors are predominately found outside of the CNS and play a role in the immune system.
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CB1 is located in the neocortex, hippocampus, basal ganglia, amygdala, striatum, cerebellum,
and hypothalamus. Activation of the CB1 receptors has been shown to assist in fear extinction
(Alger, 2014). Rey et al. (2012) conducted a study to investigate the effect of cannabinoids on
anxiety responses for CB1 receptors, GABA receptors, and glutamate neurons on genetically
modified mice and wild mice. Rey et al. measured anxiety symptoms in mice when given two
different types of cannabinoids: cannabinoids that targeted GABA-sensitive neurons and
cannabinoids targeting glutamate. The genetically altered mice were divided in two categories:
mice with no cannabinoid receptors on glutamate-sensitive neurons and mice with no
cannabinoid receptors on GABA-sensitive neurons. The cannabinoids targeting glutamatesensitive neurons both increased and decreased the anxiety of the wild mice, depending on the
dose. The genetically altered mice without cannabinoid receptors on GABA-sensitive neurons
experienced less anxiety regardless of the dosage. This experiment provided preliminary support
for the idea that dosage and cannabinoids could be altered to enhance anxiety treatment (Rey et
al., 2012). Rey et al. stated that the biphasic effects (low and high doses can produce
opposite effects) of cannabinoids in anxiety behavior is explained through anxiogenic-like
behavior through activation of CB1 receptors on GABAergic neurons from a high dose of
cannabinoids. The high dose of cannabinoids appears to partially reduce GABAergic signaling
on GABAB receptors. Rey et al.’s finding appeared to be the first neurobiological explanation of
a differential regulation of anxiety processing by cannabinoids and the interaction of the
endocannabinoid system with GABAergic and glutamatergic systems. Understanding how the
endocannabinoid system interacts with anxiety disorders shows validity for cannabinoid-based
treatments. Human trials are needed to determine if the results are applicable to humans.
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Crippa et al. (2011) conducted a study on the anxiolytic effects of CBD in social anxiety
disorder (SAD). Crippa et al. used a double-blind study with 10 male participants with a prior
diagnosis of SAD who were recruited from an epidemiological sample of 2320 university
students. The SAD diagnosis was confirmed by the Structured Clinical Interview for DSM-IV
(SCID). The severity of SAD was assessed with the Portuguese version (Osório et al., 2006,
2010) of the Brief Social Phobia Scale (BSPS; Davidson, et al., 1991). Social phobia was further
assessed using the Portuguese version (Osório et al., 2009) of the Social Phobia Inventory (SPIN;
Connor et al., 2000). Participants were considered “treatment naïve” with no comorbid mental
health disorders. All 10 participants were classified to have severe social phobia. Participants
were administered 400 mg of CBD dissolved in corn oil and packaged in a gelatin capsule or a
placebo gelatin capsule with just corn oil. The Visual Analogue Mood Scale (VAMS; Norris,
1971), translated into Portuguese (Zuardi & Karniol, 1981) was utilized to evaluate subjective
states such as calm and agitated. The participants were told to mark a point that identified their
present state on a 10cm line placed between two words that describe opposite moods. Crippa et
al. used the SPECT technique of neural imaging to compare the effects of CBD and placebo on
resting regional cerebral blood flow (rCBF) in the SAD participants, and the participants were
measured twice, one week apart. The participants reported subjective ratings on the VAMS at
five different time-points, which were 30 minutes prior to ingestion of CBD or placebo, at the
time of drug administration, at 60 minutes, at 75 minutes, and after SPECT scanning 140 min
after drug intake. The anxiety-evoking procedure consisted of the whole SPECT procedure itself,
which involves the insertion of an intravenous cannula and the exposure to a totally uncommon
situation (i.e., medical environment, large examination apparatus). The terms ‘pre-stress’,
‘adaptation’ and ‘post-stress’, refer to the moments of the scanning session in which the VAMS
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was completed. The researchers took images of each subject’s brain to monitor the activity of the
brain during a stressful event. When comparing the CBD group to the placebo group, the CBD
group had significant decreases in subjective reports of anxiety on the VAMS (VAMS; Crippa et
al., 2011).
Strengths of the Crippa et al. (2011) study included the use of a double-blind,
randomized, repeated measures, within-subject cross-over design and the study concluded that
CBD can reduce subjective anxiety in patients diagnosed with social anxiety disorder. However,
Crippa et al. conveyed that additional longitudinal research with a larger sample size and gender
diversity is necessary to confirm their findings. In addition, the fear inducing condition of the
study was the SPECT scanning, which appeared to elicit anxiety in the participants, although the
generalizability to SAD is unclear. SAD is characterized by anxiety experienced in social
situations. A naturalistic observational study that incorporated administering CBD prior to a
social event that would evoke SAD related anxiety may be needed to have a clearer
understanding of whether CBD will reduce SAD.
Linares et al. (2019) researched whether increasing doses of CBD would produce bellshaped dose-responsive curves in humans. Linares et al. reported that the study was a doubleblind placebo-controlled experiment. There was a total of fifty-seven healthy male volunteers
who participated. The setting of participant recruitment was not specified. The participants were
randomly assigned to four different groups, in which three groups were given CBD and one was
a placebo group. The four groups were given either a varying dose of CBD: 150 mg (n = 15),
300 mg (n = 15), 600 mg (n = 12), or a placebo (n = 15). The participants were administered the
Visual Analogue Mood Scale (VAMS; Norris, 1971), and physiological measures (e.g., systolic
and diastolic blood pressure, heart rate) were used to measure anxiety. Groups were matched by
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age. The average age of the placebo group was 24.5 years old, the CBD 150 mg group was 24.2
years old, CBD 300 mg group was 24.6 years old, and the CBD 600 mg group was 22.6 years
old. Groups were also matched by their years of education and socioeconomic status. Each
participant was assessed for psychiatric disorders with the Portuguese version of the Structured
Clinical Interview for the DSM-IV, clinical version (SCID-CV; First et al., 1997). Each
participant did not have a substance abuse history and did not use marijuana more than five times
in their lifetime. Baseline measurements were taken after a 15-minute adaptation period and then
was administered either a varying dose of CBD or placebo. CBD or placebo was administered 1
hour and 30 minutes prior to a simulated public speaking test (SPST; Lipper & McNair, 1972)
and another “pre-test” measurement of VAMS, heart rate, and blood pressure were taken prior to
the SPST. For the SPSR, participants were instructed that they had 2 minutes to prepare a 4minute speech about public transportation system in their city. The speech was interrupted in the
middle and VAMS, heart rate, and blood pressure measurements were taken again. After the
speech, the same measurements were taken immediately after the SPST and again after 30
minutes of the SPST. The results showed that pretreatment with 300 mg of CBD significantly
reduced anxiety during the speech compared to the placebo group according to VAMS scores.
No significant differences in VAMS scores were indicated between groups receiving CBD 150
mg, 600 mg, and placebo, which is indicative of a U-shaped dose-response curve. The U-shape
indicated that 300 mg was shown to reduce anxiety compared to the lower or higher amounts of
CBD, which did not appear to have an impact on anxiety compared to placebo. Linares et al.
indicated that a limitation to the study only showed significant results in the subjective reporting
of anxiety reduction (VAMS) and did not yield significant results for physiological effects.
(Linares et al., 2019). The study focused on healthy individuals, which makes generalizing CBD
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reduction to individuals with anxiety disorders difficult based on this study alone. The design of
the study was a double-blind placebo-controlled experiment, and each participant was matched
based on demographics, which randomizing the groups can reduce selection bias. However, the
sample size was small and the number of individuals within the conditions was also small, which
may limit power for finding robust results, and also limit generalizability. All participants were
men and generally around the age of 24, which also limits the generalizability to women and to
individuals of various ages.
Bergamaschi et al. (2011) conducted a double-blind, randomized design study to
investigate CBD’s therapeutic effect on individuals with social anxiety disorder (SAD).
Bergamaschi et al. were interested in the effects of a simulation public speaking test (SPST;
Lipper & McNair, 1972) on healthy control (HC) participants and treatment-naive SAD
participants. They recruited 2,319 undergraduate students, who were screened with the short
version of the Social Phobia Inventory (MINI-SPIN; Osório et al., 2010; Connor et al., 2001) to
identify participants with “SAD”. The participants were narrowed down to 237 male and female
participants with probable SAD based on their MINI-SPIN scores. The 237 participants were
then given a Structured Clinical Interview for the DSM-IV, clinical version (SCID-CV; First et
al, 1997), translated into Portuguese (Del-Ben et al., 2001). Twenty-four subjects were identified
to meet the criteria for SAD based on the results of their SCID-CV and MINI-SPIN and 12
individuals were selected as healthy control group (HC). The SAD patients were randomly
assigned to either the CBD group (600 mg SAD-CBD; n = 12) or the placebo group (SADPLAC; n = 12). The SAD-CBD group and SAD-PLAC group were administered either 600 mg
of CBD or a placebo 1.5 hours before the SPST. The 12 healthy controls were not given any
medication before the SPST. The Self-Statements during Public Speaking Scale (SPSS;
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Hoffmann and Di Bartolo, 2000) translated into Portuguese (de Lima Osório et al., 2008) was
administered, which is a self-report instrument that measures self-perception of performance in a
specific situation of public speaking, one subscale was used for negative self-evaluation (SSPSN). All participants were administered the Visual Analogue Mood Scale (VAMS; Norris, 1971)
to measure state anxiety levels, the Negative Self-Statement Scale (SSPS-N), and physiological
measures (i.e., blood pressure, heart rate, and skin conductance). All participants had a 15-min
adaptation period following a baseline measurement, which was followed by a single dose of
oral CBD, placebo, or no medication. Pretest measurements were made 80 minutes after the drug
ingestion. The participants received the instructions and had 2 min to prepare a 4-min speech
about the public transportation system of their city. Anticipatory speech measurements were
taken before the subject started. The speech was interrupted in the middle of their speech and
additional measurements were taken. Post-test measurements were made 15 and 35 min after the
end of the SPSS. The SAD placebo (SAD-PLAC) group presented higher anxiety, cognitive
impairment, discomfort, and alert levels when compared with the control group as assessed with
the VAMS. Pretreatment with CBD in the SAD-CBD group significantly reduced anxiety,
cognitive impairment, discomfort in speech performance, and significantly decreased alertness in
their anticipatory speech compared to the SAD-PLAC group. The SSPS-N scores showed
significant increases during the testing of the SAD-PLAC group. The SAD-CBD group showed
significant decreases in SSPS-N scores. No significant differences were observed between SADCBD and healthy control groups in SSPS-N scores or in the cognitive impairment, discomfort,
and alert factors of VAMS. Thus reveal, increases in anxiety induced by the SPST on
participants with overall SAD were reduced with the use of CBD, resulting in a similar response
as the healthy controls (Bergamaschi et al., 2011). The results of the study are similar to Linares
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et al. (2019) in that CBD use produced reduction in subjective self-report but not in physiological
measures during the SPST. Bergamaschi et al. utilized the randomized double-blind placebocontrolled design, which allowed a higher probability that their study exhibited significant results
and that CBD was the factor that reduced anxiety during the SPST. Bergamaschi et al.
acknowledged that their sample size is small, which reduces statistical power for the VAMS and
SPSS and stated that there is a need for additional randomized double-blind placebo-controlled
studies with a larger sample size and more gender diversity to confirm their findings. The use of
the SPST appeared to simulate a real-life event that can evoke anxiety, which appeared to be a
strength of the study.
Research on Medical Cannabis for Treating Depressive Disorders
Medical cannabis has shown inconsistent results for treating depressive disorders. The
Diagnostic and Statistical Manual of Mental Disorders (5th ed.; American Psychiatric
Association, 2013) has several disorders in the depressive category. Common symptoms of these
disorders indicate: depressed mood ; feeling of sadness, emptiness, or hopelessness; loss of
interest or pleasure in all or almost all activities; significant weight loss when not dieting or
weight gain; inability to sleep or oversleeping; psychomotor agitation; fatigue or loss of energy;
feelings of worthlessness or excessive or inappropriate guilt; diminished ability to think or
concentrate, or indecisiveness, and recurrent thoughts of death, recurrent suicidal ideation
without a specific plan, or a suicide attempt, or a specific plan for committing suicide.
Some research has shown exacerbation of depressive symptoms or little impact on
treatment effects with medical cannabis use. Conversely, additional research suggests medical
cannabis, as well as recreational use of cannabis, has resulted in improved symptoms of
depressive disorders. Zanelati et al. (2010) conducted a study to explore whether CBD has an
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antidepressant activity in mice in a forced swimming test. They also researched whether
antidepressant activity was contingent on 5-HT1A receptor activation and hippocampal
expression of brain-derived neurotropic factors. Male mice were dispensed CBD (extracts of
cannabis sativa plant) in 3 mg, 10 mg, 30 mg, 100 mg, or the prototype antidepressant
imipramine. The mice were forced into a swimming test or an open field arena 30 minutes after
the administration of CBD or prototype antidepressant imipramine. Another mouse group
received WAY100635 (0.1 mg·kg−1, i.p.), a 5-HT1A receptor antagonist before CBD (30 mg)
and assessment prior to the forced swimming test. CBD was shown to increase mobility in forced
swimming, which the antidepressant has a similar effect (Zanelati et al., 2010). Activation of 5HT1A receptors has been consistently related to the therapeutic effect of antidepressant drugs in
humans (Savitz et al., 2009), however a connection between these receptors and antidepressantlike effect of CBD was not investigated at that point. CBD appeared to be an agonist to the 5HT1A receptor, which has shown antidepressant-like effects that are comparable to imipramine
(anti-depressant). Additional human trials are necessary to understand if CBD would provide an
anti-depressant like effect in humans.
Khadrawy et al. (2017) conducted a study to investigate the effect of cannabis extract on
“depressive-like” rats. Twenty-four rats were placed into three groups: control, rat model of
depression induced by reserpine, and depressive-like rats treated with cannabis sativa extract (10
mg/kg expressed as Δ9-tetrahydrocannabinol). The rat model of depression was induced by
olfactory bulbectomy, which was identified as an alteration in brain rewards function produced
in by the cannabinoid CB1 receptor agonist WIN%%-212,2, and a dopaminergic receptor. The
rats were measured in an open field test. No significant differences were noted in open field test
results between depressive-like rats treated with cannabis and other rat groups. Significant
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differences in open field tests were found between the rat model of depression induced by
reserpine rats and control rats. The depressive-like rats had a significant decrease in motor
activity that was assessed by the open field test compared to control rats and rat model of
depression rats. The results suggest that cannabis sativa may increase motor deficits, increasing
depressive symptoms and memory impairment (Khadrawy et al., 2017).
Round et al. (2020) conducted an observational cohort study of 37,338 patients receiving
medical cannabis between 2014 and 2019. The patients were administered the Patient Health
Questionnaire (PHQ-9; Kroenke & Spitzer, 2001), a self-report measure to assess for depression.
Adults of any race, SES, or gender seeking medical cannabis from authorized cannabis clinics
were included in the study. Any individual who did not complete in the PHQ-9 on the follow-up
questionnaire at baseline were excluded, which resulted in a total of 5,103 patients of various
ages, SES, and genders. Participants used various routes of administration, which included
ingesting, smoking, vaping, or topical use. A subcategory of participants also endorsed
antidepressant usage that included selective serotonin reuptake inhibitors (SSRI), serotoninnorepinephrine reuptake inhibitors (SNRI), tricyclic antidepressants (TCA), and other
antidepressants. Other antidepressants included norepinephrine-dopamine reuptake inhibitors,
noradrenergic and specific serotonergic antidepressants, and monoamine oxidase inhibitors
(MAOI). The PHQ-9 was administered at baseline and follow-up scores for the PHDQ9 were
obtained after at least 6 months of medical cannabis use. Of 5103 participants who had baseline
and follow-up scores for the PHQ-9, 50% met the criteria for depression at baseline. After 6
months of medical cannabis use, 4855 participants reported no clinically significant changes in
their PHQ-9 scores, 172 participants reported clinically significant improvements in depressive
symptoms, and 76 participants reported an increase in depressive symptoms (Round et al., 2020).
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Based on these results Round et al. (2020) concluded there was no major impact of
medical cannabis as a treatment for depressive symptoms. Major limitations in the study were
the variations in the types of medical cannabis used and in the dosage consumed by the
participants. Therefore, it is difficult to formulate the treatment impact on depressive symptoms
without knowing which medical marijuana product is being utilized and at what doses,
frequency, and amount. Also, a majority of participants did not have follow up PHQ-9 scores and
therefore were not included or assessed. Finally, use of the one short self-report measure at one
point in time is likely to miss changed in depression and cannot assess at what points following
medical cannabis use changes might occur.
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CHAPTER III. RECREATIONAL USE AND MISUSE OF MEDICAL MARIJUANA
Abizaid et al. (2019) conducted a review of available research and studies from 2003 to
2018 on treating PTSD and other mental health disorders with cannabis from. Abizaid et al.
conveyed that there are both positive and negative outcomes repeated in the literature for treating
mental health with cannabis that has a limited number of clinical trials conducted, the true
benefit or adverse effects of cannabis is difficult to assess currently. The available research
suggests that the use of cannabis could have potentially harmful effects such as cognitive
disturbance and impaired neuronal plasticity and organization in the adolescent brain. Medical
marijuana may create functional brain changes, be a risk factor for marijuana abuse, and may
increase the symptoms of schizophrenia. Abizaid et al. indicated that the neurobiological
mechanisms involved in PTSD are not yet completely understood studies how typically used
animal models in an attempt to gain understanding of associated areas in the brain, and these
models may not generalize to humans. Additional research needs to be conducted to have a better
conceptualization of all the associated brain areas involved (Abizaid et al., 2019).
Impact of Recreational Use or Misuse of Cannabis on PTSD
Wilkinson et al. (2015) investigated the effects of marijuana use and PTSD symptom
severity in a longitudinal observational study from 1992 to 2011. There were 2,276 participants
who were veterans diagnosed with PTSD based on DSM-III criteria (until 1994) and then DSMIV criteria subsequently. The participants were admitted to a specialized intensive VA treatment
program for PTSD with assessments conducted at intake and 4 months after discharge. PTSD
symptom severity was also measured using the Short Form of the Mississippi Scale (MISS;
Fontana, 1994). No participants had been prescribed medical marijuana in the past, and their
drug and alcohol use was assessed with the Addiction Severity Index (ASI; McLellan et al.,
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1985). Violent behavior was assessed using a four-item self-report questionnaire from the
National Vietnam Veterans Readjustment Study (Kulka et al., 1990). Community adjustment
was measured by several factors which included: employment status, violent behavior, history of
incarceration, and whether the veteran was planning on attending military reunions after
discharge. The average age of the participants was 51.7 years old with 96.7% being male. The
average length of stay in the program was 42.5 days. The participants were classified into four
groups: no use at admission “never-users”; used at admission but not after discharge “stoppers”;
used at admission and after discharge “continuing users”; and use after discharge but not at
admission “starters”. The analysis of covariance compared groups on follow-up for PTSD
symptoms, drug and alcohol use, violent behavior, and employment. The results at baseline were
the following: continued marijuana use was significantly associated with worse outcomes in
PTSD symptom severity (MISS scores), violent behavior, and measures of alcohol and drug use
(ASI) compared to stoppers and never-users. The follow-up results: Stoppers and never-users
had the lowest levels of PTSD symptoms (MISS), and starters had the highest level of violent
behavior. Wilkinson et al. concluded that starting marijuana use after psychological treatment
may worsen PTSD symptoms, increase violent behaviors, and increase alcohol use. Also, they
concluded marijuana may decrease the effectiveness of PTSD treatment (Wilkinson et al., 2015).
However, the longitudinal observational study incorporated within subject repeated
measurements and between subject design that provided correlational data. The study does not
provide insight on types of marijuana used, frequency, dosage, and amounts consumed per use,
which affects the ability to control for those and other factors that can potentially have an impact
on the results. Wilkinson et al. conveyed that another limitation of the study was the fact it was
not randomized, and the groups could not be considered to have equal time in the program.
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Therefore, on the basis of this study, casual relationships cannot be made between marijuana use
and PTSD severity, drug and alcohol use, and violent behavior. The information in the study
does not correlate with a past studies (Elms et al., 2019 & Roitman et al., 2014) that suggest
marijuana can potentially improve PTSD symptoms. While this study suggests that marijuana
use may worsen PTSD symptoms, additional clinical trials are necessary to either support or
contrast with these findings.
Bonn-Miller et al. (2013) conducted a study to investigate the association between
current cannabis use disorder and changes in PTSD symptoms over time after discontinuation of
cannabis use. The study was longitudinal and consisted of 260 male combat-exposed military
veteran patients diagnosed with PTSD and admitted to a VA residential rehabilitation program
for PTSD between 2000 and 2008. The average length of stay for the participants was 78.07 days
but any veteran who completed any amount of treatment was included in the study. Eighty-one
of the participants met the criteria for cannabis use disorder. PTSD symptoms were measured by
the Structured Clinical Interview for DSM–IV - Clinician Version (SCID-CV; First et al., 1997)
and the PTSD Checklist - Military Version (PCL–M; Weathers, et al., 1993). Psychological
distress was measured using the Beck Depression Inventory (BDI; Beck, Steer, & Garbin, 1988).
Trauma severity was also measured by using the Combat Exposure Scale (CES; Keane et al.,
1989). All the participants were measured at two time periods, which were within the first week
of intake and during the final week during discharge. SCID–CV, BDI, PCL-M, and CES
information was gathered at intake and the PCL-M was administered at discharge. The results
indicated that participants reported high PCL-M scores at treatment intake (M = 66.25) and the
PCL-M scores were reduced at the time of discharge (M = 62.37). Participants with cannabis use
disorder results did not report higher PCL-M scores at intake, but participants with cannabis use
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disorder reported lower levels of improvement in the PCL-M at discharge (Bon-Miller et al.,
2013).
Bon-Miller et al. (2013) indicated that their results do suggest that marijuana may worsen
PTSD symptoms. However, their results can only be generalized to men. In addition, the
longitudinal design only provides correlational data, so no causality can be obtained from their
results. Another concern is that the claim that marijuana may worsen PTSD symptoms is based
on the notion that individuals with cannabis use disorder showed less improvement in their
PTSD symptoms in the absence of the drug. However, the results are more suggestive of the idea
that individuals with cannabis use disorder recover at a reduced rate compared to other
individuals with PTSD without cannabis use disorder.
Tull et al. (2016) designed a study to investigate the role of marijuana dependence on
PTSD and subjective and biological emotional reactivity in response to a trauma cue.
Participants consisted of 202 male and females with or without current PTSD admitted to a
substance use disorder treatment facility with at least one potentially traumatic event
experienced. The participants were administered diagnostic interviews and asked for subjective
emotional reactivity to experienced traumatic events, and their biological reactivity was
measured with saliva samples. Substance use was measured by the Structured Clinical Interview
for DSM-IV Axis I Disorders (SCID-I; First et al., 1996). PTSD was diagnosed during an
interview using the DSM-IV version of the Clinician-Administered PTSD Scale (CAPS; Blake et
al., 1990). The participants also were administered the Mini International Neuropsychiatric
Interview, Version 6.0 (MINI; Sheehan et al., 2009) to assess for current DSM-IV Axis I
disorders with the exception of PTSD and SUD. Borderline personality disorder module of the
Diagnostic Interview for DSM-IV Personality Disorders (DIPD-IV; Zanarini et al., 1996) was
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utilized to identify borderline personality disorder. The participants were split into two groups:
substance abuse disorder (SUD) with PTSD and SUD without PTSD. Both groups were asked to
describe their traumatic events and an associated distress while being video recorded. To assess
for subjective emotional reactivity to the traumatic events, the participants were administered the
negative affect (NA) subscale in the Positive and Negative Affect Scales (PANAS; Watson et al.,
1988). Saliva samples were taken at two different time periods, which were before talking about
the trauma and 20 minutes after talking about the trauma. Marijuana frequency of use was
assessed using the Drug Use Questionnaire (DUQ; Hien and First, 1991). The study involved
two sessions on separate days with an average time between sessions of 6.23 days. The initial
session consisted of completion of the above assessments, and participants were recorded during
their time describing their traumatic experience. In the second session the participants listened to
their recording from the previous session and were instructed to close their eyes and imagine the
event and then were administered the PANAS-NA and given saliva samples 20 minutes after the
task. The results suggested that PTSD was associated with greater subjective emotional reactivity
(PANAS-NA) to the trauma script only among participants without marijuana dependence. Also,
marijuana dependent participants with or without PTSD reported less subjective emotional
reactivity (PANAS-NA) compared to the participants with PTSD but without marijuana
dependence (Tull et al., 2016).
Tull et al.’s (2016) study had a design that focused on between-subject and within-subject
comparisons that provided correlational results. Their results found that individuals with
marijuana dependence had less subjective emotional reactivity towards their trauma scripts
compared to individuals with PTSD without marijuana dependence. The authors speculate that
these results may be due to the high density CB1 cannabinoid receptors in the amygdala, which
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with intake of THC (CB1 agonist), can lead to reduced activation in the amygdala, therefore
resulting in reduced emotional reactivity. Tull et al. also postulated that their results may suggest
that participants with marijuana dependence and PTSD may have a greater tendency to avoid
negative emotions, but this claim appeared to be speculation and is not supported by data.
Alternatively, the scores may be interpreted as marijuana dependent participants with PTSD may
improve their emotional reactivity and thus yielding lower subjective reporting. Without the use
of clinical trials that involve randomized double blind placebo control designs, the impact of
marijuana dependence on PTSD is unclear, and causality cannot be assessed. Other limitations
were that variations in the extent to which participants were able to successfully reimagine the
trauma script were not measured or accounted for.
Impact of Recreational Use or Misuse on Anxiety
Rusby et al. (2019) conducted a review of an ecological momentary assessment (EMA)
study of social influences of risky behavior in adolescence in order to understand the relationship
between marijuana use and anxious mood lability during early to mid-adolescence. The EMA
study was extrapolated from a larger study that focused on investigating social influences of
risky behaviors during adolescence and consisted of 1,188 students. The EMA study occurred
from 2014 to 2017 and male and female students completed brief random surveys over a 4-day
period beginning in eighth grade and ending when they were in 10th grade. The survey consisted
of 10 quarterly assessment waves and was administered at 18 random times per assessment
wave, which resulted in a total of 180 possible EMAs per participant. The EMA asked questions
about mood, current activities, and social context during non-school hours. Mood lability was
extrapolated out of the EMA and used to assess for an average anxious mood lability score
(MSSD). The participants also completed brief surveys in the spring of eighth grade, and fall,
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winter, and spring of ninth and 10th grade. These surveys assessed for adolescent substance use
in their lifetime and within the past 30 days and asked about marijuana use for an overall of
seven different time periods. Marijuana use was assessed with the Oregon Healthy Teens Survey
(Boles, Biglan, & Smolkowski, 2006). A total of 466 eighth grade participants were included in
the study. The results showed that 8% to 13% endorsed using marijuana recently across the
assessment waves. Participants had higher reported scores on MSSD (anxious mood lability)
when reporting recent marijuana use compared to the MSSD scores without recent marijuana use
(Rusby et al., 2019).
Although, Rusby et al. (2019) utilized quantitative survey information from a
longitudinal study and found that recent marijuana use was associated with higher anxious mood
lability, these findings have several areas of weakness. The research does show a correlation
between the two variables. However, the sample size of individuals who used marijuana recently
was rather small, which affects the power of the results. Also, recent marijuana use is considered
in the last 30 days but there can be significant variability in the impact from marijuana in a
person who used marijuana 30 days ago opposed to the day before being surveyed. Also, Rusby
et al. reported that their results can only apply to youth who live in rural and suburban
communities, and the MSSD scores of anxious mood lability do not indicate that anxiety was
interfering with the participants’ lives. Finally, the MSSD is not validated, and therefore the
results should be viewed with caution due to use of a measure that is not validated as a primary
outcome measure.
Impact of Recreational use or Misuse on Symptoms of Depression
Bahorik et al. (2018) conducted research concerning medical versus nonmedical
marijuana use as a treatment for depression. There hundred and seven psychiatry outpatients
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were the participants in a trial of medical marijuana use treatment for individuals with
depression. The Patient Health Questionnaire (PHQ-9; Kroenke & Spitzer, 2001) was used to
determine depression severity and suicidal ideation. Functional outcomes were measured with
the Short Form 12 Health Survey (SF-12; Turner-Bowker & Hogue, 2014), which is a self-report
questionnaire and consists of physical and mental health subscales. Marijuana use in the past 30
days was assessed during interviews at baseline, 3, 6, and 12 months. The data was collected
from participants in a randomized controlled trial with the use of motivational interviewing for
medical marijuana use treatment in depressed individuals. The participants were randomized into
one of two studies after they completed screen procedures, which were motivational interviewing
(MI) or treatment control. Results at baseline were that 40.0% of the sample used marijuana. The
MI group had a 45-minute motivational interview session followed by two 15-minute telephone
booster sessions that were about 2 weeks apart. The control group were given two brochures on
the risks specific to the substances they had reported at baseline and received “usual depression
care”, which consisted of medication management and individual psychotherapy. Of the 40.0%
of participants who used marijuana at baseline, 28.2% used marijuana for medicinal purposes.
Participants who used non-medicinal marijuana showed a higher level of depression severity
(PHQ-9), suicidal ideation, poorer mental health functioning (SF-12), and fewer psychiatry visits
compared to participants who did not use marijuana. Participants using medicinal marijuana had
significantly worse mental health and physical health functioning, a higher level of depression
severity, and poorer everyday functioning compared to non-users. After 1 year, non-medicinal
marijuana users were less likely to have psychiatry visits and had poorer mental health
functioning compared to non-users. Patients using non-medical marijuana for over 1 year had
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significantly less improvement in depression symptoms and suicidal ideation compared to nonusers (Bahorik et al., 2018).
Bahorik et al.’s (2018) study was longitudinal and focused on between subject and within
subject results. The researchers specified that their results are only generalizable to an outpatient
psychiatry setting of insured patients in San Francisco area. The PHQ-9 scores that were
included into the study may not reach the threshold for a diagnosis of major depressive disorder
(MDD) through the DSM, which indicates that many of the participants may not have met the
criteria for MDD. The results tended to focus on cross sectional data between medicinal users,
non-medicinal users, and non-users, without highlighting the differences of treatment (MI versus
control) in their results.
In contrast, Denson and Earleywine (2006) conducted a study to investigate the
relationship between depression and marijuana use. They hypothesized that marijuana use might
inhibit the likelihood of depressive symptoms improving, especially in nonmedical marijuana
use. The goal was to find participants who were significantly depressed and used marijuana to
include in the study. Denson and Earleywine used an internet survey for 4,494 male and females
who endorsed using cannabis either daily (n = 3323), once a week or less (n = 861), or never (n =
310). Medical use of cannabis was identified by the participants during the survey, and the
common conditions for use were nausea, vomiting, cancer, attention deficit, and poor appetite.
The Center for Epidemiologic Studies Depression scale (CES-D; Radloff, 1977) was
administered to identify depressed affect, positive affect, somatic and psychomotor retardation
activity, and interpersonal symptoms. The results revealed that medical cannabis users reported
more depression than recreational users. However, non-users reported more depression than
recreational users. Medical users also reported more somatic complaints than recreational users.
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However, weekly users had less depressed mood, more positive affect, and fewer somatic
complaints than non-users (Denson & Earleywine, 2006).
Denson and Earleywine’s (2006) research appeared to be the first research that compared
recreational users of cannabis, medical users of cannabis, and non-users. The study results may
be skewed from those that would be seen in the general population due to selecting participants
who were the “most depressed” of all the individuals they surveyed. The design of the study
focused on cross sectional between subject measurements, so no causality can be ascertained
from their results. Also, medical users had aliments like cancer, nausea, and vomiting, which
also may impact depressive symptoms. Overall, studies that survey community samples but leave
no way of verifying medicinal (i.e., prescription) versus recreational users are based on selfreport, which is less reliable than verified data.
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CHAPTER IV: INTEGRATION OF MEDICAL MARIJUANA USE VERSUS
RECREATIONAL MARIJUANA USE OR MISUSE
Synthesis of the Data on PTSD
When examining the treatment of PTSD with marijuana, it is important to distinguish
between medical marijuana and recreational use or misuse. Focusing on medical marijuana first,
it can come in several forms, with the two major categories being THC and CBD. Both CBD and
THC come in various administration routes (i.e., smoked, vaped, and ingested). The dosage of
medical marijuana is important for treatment implications and is rarely consistent across
available research. Another consideration is viewing how treatment effects are being measured,
whether self-report, clinical interpretation, or biological measures (e.g., vitals, MRIs, CTs).
When discussing symptom reduction, what symptoms are being reduced and to what extent? The
challenge is to compare effective treatment across various research studies with a lack of
consistency in these factors. Available research that compared THC and CBD has been
extremely limited. LaFrance et al. (2020) found that individuals with PTSD reported a 62%
reduction in intrusive thoughts, 51% reduction in flashbacks, 67% reduction in irritability, and
57% reduction in anxiety when measuring before and after inhaling cannabis. Higher doses were
used to manage anxiety. Individuals with higher severity in symptoms showed a larger reduction
in symptom severity. There was no significant difference in symptom changes when comparing
THC to CBD. Overall, cannabis intoxication appeared to assist in temporary relief from PTSD
symptoms. However, the results indicated that individuals’ baseline PTSD symptom ratings
showed no change over time. (LaFrance et al., 2020).
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THC
PTSD symptom reduction has been shown when using medical THC. In a 3-week trial,
synthetic oral extracts such as nabilone have shown a reduction in hyperarousal symptoms,
reduced nightmares, and improved sleep quality with a dosage range from 2.5 mg to 5 mg
administered below the tongue (Roitman et al., 2014). Cameron et al., (2014) indicated that
nabilone use with a dosage from 1.4 mg to 4.0 mg for an average of an 11.2 weeks showed a
reduction in nightmares and sleep quality/time improvement were reported. Nabilone is a C1
receptor agonist, which is spread throughout the brain and has limited interaction with
cardiorespiratory areas in the brain stem (Cameron et al., 2014). Frazer (2009) conducted the
research on “treatment-resistant” individuals who have tried medication interventions to treat
their PTSD symptoms. Frazer found that participants reported a clinically significant reduction in
the severity of trauma-related nightmares (Fraser, 2009). Nabilone has been shown to have low
indicators of abuse potential (Ware & St. Arnaud-Trempe, 2010). However, Fugh-Berman et al.
(2020) suggest that nabilone use has potential abuse for individuals with substance abuse history
due to the potential to experience euphoria.
Nabilone appeared to have the highest therapeutic advantages for the treatment of PTSD
symptoms. Research has consistently found a reduction in nightmares and improvement in sleep
quality. Effective dosage appeared to range from 0.2 mg to 4.0 mg, with a trend towards the
higher end of dosage (Frazer, 2009). Individuals who reported psychosis were typically excluded
from these trials due to the potential to exacerbate their symptomology, but this claim had not
clearly been documented. No gender differences have been noted, but gender differences have
rarely been studied.
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CBD
CBD has been shown to be effective in treating symptoms of PTSD. CBD is theorized to
increase the consolidation of extinction learning (Das et al. 2013), which may potentially aid in
the extinction of traumatic memories using 32 mg of inhaled CBD. Similar to nabilone, CBD has
been shown to reduce PTSD-related nightmares. Additional support for CBD treatment of PTSD
examined the impact of either oral CBD capsules or liquid spray CBD with an average dose
between 33.18 mg to 48.64 mg over eight weeks. Overall, a reduction in frequency and intensity
of PTSD symptoms was noted (Elms et al., 2019).
It is challenging to draw conclusions and commonality on limited research for the
therapeutic effectiveness of CBD. With the available research, it appeared that the “effective
dosage” can range from around 30 mg to 50 mg of CBD administered daily (Das et al., 2013;
Elms et al., 2019). Best route of administration cannot be determined based on the available
research. While studies have shown that CBD may increase the consolidation of extinction
learning, the theory has not been extensively studied on individuals with PTSD. In current
studies, CBD is typically administered following an induced fear response, which may or may
not mimic PTSD symptoms. Medical marijuana may also create functional brain changes, which
may increase symptoms of schizophrenia and may be a risk factor for marijuana abuse (Abizaid
et al., 2019).
Marijuana Use and Misuse
Nonmedical cannabis use has been shown to be related to cognitive disturbances and
impaired neuronal plasticity and organization in an adolescent brain (Abizaid et al., 2019).
Marijuana use was associated with increased PTSD symptom severity, violent behavior, and
higher rates of alcohol and drug use in veterans diagnosed with PTSD and admitted to a
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specialized intensive VA treatment program for PTSD. Also, starting marijuana use after
psychological treatment for PTSD may contribute to worsening of PTSD symptoms and may
decrease the effectiveness of PTSD treatment compared to individuals who stopped or never
used marijuana (Wilkinson et al., 2015). Marijuana use has also been shown to increase PTSD
symptoms. A positive correlation was noted between higher amounts of marijuana use, and
increases PTSD symptoms (Bonn-Miller et al., 2010). In terms of marijuana misuse, Individuals
with cannabis use disorder were likely to experience lower levels of PTSD symptom changes
(Bonn-Miller et al., 2013). Additional research found no more significant differences in
subjective reactivity for individuals with PTSD and marijuana dependence than individuals with
PTSD without marijuana dependence, although this may be due to the idea that marijuanadependent individuals may have alterations in their emotional processing in response to a trauma
cue and thus may generally show lower emotional reactivity (Tull et al., 2016).
Synthesis of the Data on Anxiety
The limited research on medical marijuana treatment for anxiety disorders has examined
use of CBD. Studies that focused on THC were limited. Two studies identified that THC use has
shown reduction in self-reported anxiety (Feingold et al., 2017; LaFrance et al., 2020). The
factors of administration routes (i.e., smoked, vaped, and ingested), how treatment effects are
being measured (i.e., using self-report, clinical interpretation, or biological measures), and
dosage was considered. The challenge was to compare effective treatment across various
research with limited consistency in these factors. Another challenge was comparing various
anxiety disorders with medical marijuana treatment, considering that there was no universality
with types of medical marijuana used for treatment, and there were a lack of double-blind
studies.
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CBD
Individuals with SAD were shown to have significant decreases in subjective reports of
anxiety compared to placebo. The participants with SAD were administered 400 mg of CBD,
which appeared to be an effective dose to reduce anxiety (Crippa et al., 2011). Additional
research on SAD and CBD treatment concluded that pretreatment with 600 mg of CBD showed
significant reductions in anxiety, cognitive impairment, discomfort in speech performance, and
significantly decreased alertness in anticipatory speech compared to SAD placebo groups
(Bergamaschi et al., 2011). Regarding performance anxiety, “healthy individuals” administered
300 mg of CBD as a pretreatment have shown significant reductions in the Visual Analogue
Mood Scale (VAMS) compared to placebo. VAMs was used to evaluate subjective states such as
calm and agitated. However, in this study, individuals receiving 150 mg of CBD, 600 mg of
CBD, or placebo did not yield significant differences in VAMS scores (Linares et al., 2019). The
differences between the studies regarding optimal dose may be due to the differences within the
design and participant selection. Two studies (Crippa et al., 2011; Bergamaschi et al., 2011)
included participants with social anxiety disorder (SAD), whereas the other study (Linares et al.,
2019) exclusively included participants without significant levels of anxiety. Individuals with
anxiety may require a higher dose of CBD to reduce anxious symptomology. Crippa et al.
indicated that the effective dose of CBD to reduce SAD symptoms was 400 mg. However,
Bergamaschi et al. reported that 600 mg of CBD was found to be an effective dose to reduce
SAD symptoms. Both Crippa et al. and Bergamaschi et al. only used one dose of CBD to
compare to placebo groups and control groups. Thus, future research on various dosages of CBD
use is needed to determine its effectiveness in reducing SAD symptoms.
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Marijuana Use and Misuse
There has been limited research conducted on marijuana use and misuse and anxiety
disorders. Some research has focused on rats exposed to cannabis smoke or various doses of
THC. Results were inconclusive and non-significant.
Synthesis of the Data for Depression
The research has been inconsistent in the effectiveness and benefits of medical marijuana
treatment for depression. Research has provided contradicting results regarding reducing
symptomology or exacerbating depressive symptomology. Due to the lack of research, treatment
effectiveness determination is difficult to discern with certainty.
Medical Marijuana Treatment
CBD was utilized as an antidepressant on male mice with doses of from 3 to 100 mg. The
mice given CBD were shown to increase mobility in forced swimming activities; mice
administered antidepressants had similar effects (Zanelati et al., 2010). However, dosage and
depressive symptom reduction cannot be compared to human subjects due to CBD being tested
on mice. The research implications are that CBD may combat motor deficit effects of depression,
although the claim cannot be substantiated from the research available. Results of additional
research on “depressive-like” rats administered a cannabis sativa extract (10 mg/kg expressed as
Δ9-tetrahydrocannabinol) suggest an increase in motor deficits, depressive symptoms, and
memory impairment (Khadrawy et al., 2017). The major difference in these two studies is the
rodents being administered CBD or THC forms of marijuana. CBD appeared to reduce the
impact of motor deficits caused by depression, and conversely, THC appeared to worsen motor
deficits and depressive symptomology.
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In the study of human participants, medical cannabis was utilized as a treatment for
depression using various administration routes, which included ingesting, smoking, vaping, or
topical use. Depressive symptoms were assessed and measured by the PHQ-9. Of 5103
participants, 172 reported significant improvements in depressive symptoms, 76 reported an
increase in depressive symptoms, and 4855 reported no clinically significant changes, based on
PHQ-9 scores (Round et al., 2020). A major limitation in the study was the types of medical
cannabis used and the participants’ dosage, as well as limited data on changes in depression over
time. Therefore, it is difficult to formulate the treatment impact on depressive symptoms without
knowing which medical marijuana product is being utilized, and without studies with more
robust assessments of symptom change.
Marijuana Use and Misuse
One study examined medical marijuana users with depression versus nonmedical
marijuana users with depression. The research highlighted that both nonmedical marijuana users
and medical marijuana users had worse mental health functioning than individuals with
depression who did not use any form of marijuana. Nonmedical marijuana users had higher rates
of suicidal ideation compared with non-users. Medical marijuana users had worse mental and
physical health functioning when compared to non-users (Bahorik et al., 2018). This study
suggests that either medical or nonmedical use of marijuana can worsen depressive symptoms
and negatively impact psychological and physical health functioning. Conversely, in another
study individuals using nonmedical marijuana once per week and daily users reported less
depressed mood, more positive affect, and fewer somatic complaints than non-users. When
comparing medical versus recreational use, medical users indicated more depressed mood and
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somatic complaints than recreational users. However, a confounding variable may be medical
conditions impacting depressive symptoms (Denson & Earleywine, 2006).
Who Should Be Prescribed Medical Marijuana?
Based on the available research, several studies have shown both positive and negative
indicators for prescribing medical marijuana for PTSD, anxiety disorder, and depressive
disorders. The goal was to find the best practices and considerations that should be considered
when using medical marijuana as a treatment modality for these mental health disorders. The
following conclusions were not approved by any medical committee and should be taken as
considerations and not medical guidelines to prescribing medical marijuana. Medical marijuana
appeared to have benefits for reducing and managing symptoms of PTSD and anxiety disorders.
Depressive disorders do not have clear indicators of treatment success or symptom reduction
based on available research.
PTSD
There are indicators that both THC and CBD have shown symptom reduction for PTSD.
No significant differences were found in symptom reduction for PTSD when comparing THC to
CBD (LaFrance et al., 2020). THC has been shown to reduce hyperarousal, reduction in
nightmares, and improve sleep quality. Many of the THC studies involved nabilone, a synthetic
extract from the medical cannabis flower. The “effective dose” appeared to range between 0.2
mg to 4.0 mg (Frazer, 2009); height and weight should be considered for dosage. THC may be
beneficial to prescribe to PTSD patients with predominant concerns related to nightmares and
sleep quality. However, nabilone may cause dizziness, drowsiness, dry mouth, and euphoria.
Nabilone has also been associated with hypotension and hypertension; individuals with
cardiovascular disease may be at higher risk for health complications. Individuals with PTSD
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and substance abuse history may not be a suitable fit due to the experience of euphoria while on
nabilone and the potential for abuse. Individuals who also experience psychosis and/or
depression may be at risk of exacerbating depressive symptoms, hallucinations, or psychosis
using nabilone. Nabilone has not been studied on women during pregnancy and has only been
studied on pregnant animals, which have been shown to have increased embryo lethality, fetal
resorptions, decreased fetal weight, and pregnancy disruptions. The FDA does not recommend
breastfeeding while on nabilone because some cannabinoids are excreted in breast milk (FughBerman et al., 2020).
CBD has also been shown to improve symptoms of PTSD. CBD has been correlated with
the consolidation of extinction learning, potentially helping to promote extinction in traumatic
memories. CBD has also been shown to reduce PTSD-related nightmares. With the available
research, it appeared that the “effective dosage” can range from around 30 mg to 50 mg of CBD
administered daily. CBD has been shown to have an anxiolytic effect to help reduce anxietyrelated symptoms synonymous with PTSD. CBD also does not lead to euphoria in contrast with
flower cannabis that contains THC. However, CBD can cause dry mouth, diarrhea, reduced
appetite, and fatigue. CBD also has interactions with other medications such as blood thinners,
heart rhythm medication, thyroid medication, and seizure medications, and thus it is important to
consult a doctor prior to CBD use (Bykov, 2021). Therefore, CBD may be an appropriate fit for
individuals with PTSD who have related nightmares and experience high anxiety levels. CBD
may provide extinction learning of traumatic memories, but more research is needed to replicate
these findings. Individuals with substance use may be an appropriate fit to use CBD due to the
absence of THC, which may reduce abuse potential.

61
Medical cannabis flower has not been extensively researched. Many studies are based on
self-report, case reports, and observational studies and include both medical cannabis use and
nonmedical cannabis use. Research has suggested that cannabis (medical or non) can create
cognitive disturbances and may create other functional brain changes such as impaired neuronal
plasticity and organization in adolescents (Abizaid et al., 2019). Additional research suggests
that marijuana use was associated with worse PTSD symptom severity, violent behavior,
decreased effectiveness of other PTSD treatments, and increased drug and alcohol use compared
to individuals who never used marijuana or stopped using marijuana (Wilkinson et al., 2015).
This research implies that marijuana use after the start of treatments can decrease the
effectiveness and worsen PTSD symptoms overall. Therefore, using flower medical cannabis or
nonmedical cannabis as a treatment for PTSD may be associated with increased symptomology
and worse outcomes. However, flower medical cannabis or nonmedical cannabis efficacy is
difficult to measure, and additional research is required to help substantiate any claims that there
is a therapeutic benefit or significant harm.
Focusing primarily on flower cannabis abuse, individuals with cannabis abuse
experienced lower levels of PTSD symptom change over time. Marijuana abuse appeared to
adversely impact PTSD symptoms (Bonn-Miller et al., 2013). In addition, research also supports
that marijuana utilized for coping can exacerbate PTSD symptoms; higher levels of PTSD
symptoms were associated with higher levels of marijuana use for coping in contrast to
recreational use of cannabis (Bonn-Miller et al., 2010). Individuals with marijuana dependence
may experience alternations in their emotional processing in response to a trauma cue (Tull et al.,
2016). In conclusion, marijuana abuse may worsen PTSD symptomology. Prescribing medical
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marijuana to an individual with cannabis use disorder may have more potential risks than
benefits, but additional research is needed.
Anxiety
Research on medical marijuana and nonmedical marijuana as a treatment for various
anxiety disorders is limited. The available research consists of examining anxiety in general and
does not always designate which anxiety disorder is the focus. CBD appeared to have anxiolytic
effects to help reduce anxiety. Individuals with SAD have shown a reduction in self-reported
anxiety when administered 400 mg of CBD (Crippa et al., 2011). Additional research suggests
that CBD reduced anxiety for public speaking with a dosage of 300 mg. However, in this study,
150 mg of CBD and 600 mg of CBD did not yield any differences in anxiety reduction (Linares
et al., 2019).
Conversely in other research, 600 mg CBD was shown to reduce anxiety if used prior to
an anxiety-provoking event such as a speech performance. CBD can also reduce cognitive
impairment, discomfort in performance, and decreased alertness (Bergamaschi et al., 2011).
Therefore, based on available research, conclusions on the effectiveness of CBD are applied to
social anxiety and social performance. Also, the dose of CBD effectiveness may vary among
individuals, and additional research is needed to understand the effective dosage. Additional
research is also needed for other various anxiety disorders to determine if CBD is an adequate
treatment. Individuals with substance use or abuse and SAD may benefit from symptom
reduction with the added benefit of reduced abuse potential. CBD side effects should also be
taken into consideration when prescribed. CBD can cause dry mouth, diarrhea, reduced appetite,
and fatigue. Again, CBD does have interactions with other medications such as blood thinners,
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heart rhythm medication, thyroid medication, and seizure medications; it is important to consult
a doctor prior to CBD use (Bykov, 2021).
Medical marijuana has been shown to reduce anxiety and depression for patients with
chronic pain compared to patients utilizing prescription opioids. (Feingold et al., 2017). Among
mental health disorders, anxiety is among the highest reasons for prescribing medical marijuana
(Kosiba et al., 2019). Research also reports that individuals prescribed medical marijuana for
anxiety have shown a significant decrease in anti-anxiety medication use (Piper et al., 2017).
However, benefits and risks have not been adequately studied despite the frequency with which
medical marijuana is prescribed for anxiety.
In conclusion, medical marijuana may provide an anxiolytic effect in treating anxiety
disorders, although dosage and type of medical marijuana are not clear to provide maximum
benefit are not clear. Different strains of medical marijuana have various concentrations of THC,
which adds additional confusion on what amount of medical marijuana is appropriate for the
user. However, studies regarding THC as a treatment for anxiety in humans are absent. (Mayo
Clinic, 2020).
Depression
Medical marijuana appeared to have the lowest therapeutic benefits for individuals with
depressive disorders. However, there is limited research providing clarification on the
therapeutic benefits of medical marijuana for depression. CBD has shown antidepressant
qualities in mice (Zanelati et al., 2010), but humans may not necessarily have the same results.
CBD may provide relief in depressive symptoms, although additional research on humans is
needed to provide clarity. THC extract research has suggested that worsening depressive
symptoms, motor deficits, and memory impairment were found for “depressive-like” rats
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(Khadrawy et al., 2017). Again, it is difficult to conclude the efficacy of treatment with a THC
extract as applied to humans. Limited available research suggests that medical cannabis does not
have a major impact on depressive symptoms and may worsen depressive symptoms (Round et
al., 2020). Due to the limited research and lack of consistency among types of medical
marijuana, quantity and frequency used, and administration route, conclusions are difficult to
derive.
Research that focused on medical vs. nonmedical marijuana use for depression is limited
and inconsistent. Medical marijuana has been shown to worsen mental and physical health
functioning. Also, nonmedical users showed an increase in suicidal ideation rates, worse mental
health functioning, and less improvement over time than non-users (Bahorik et al., 2018).
Conversely, nonmedical cannabis users had less depressed mood, more positive affect, and fewer
somatic complaints than non-users. When comparing medical versus recreational use, medical
users had more depressed mood and somatic complaints than recreational users. However, a
confounding variable may be medical conditions impacting depressive symptoms (Denson &
Earleywine, 2006). Due to inconsistencies and lack of research, conclusions cannot be made to
determine whether medical or nonmedical cannabis use increases or reduces depressive
symptoms. Individuals with depression may not be best suited for medical marijuana due to the
potential risks. Individuals who are prescribed medical marijuana should be monitored for
worsening symptoms and suicidal ideation.
Cannabis can have an impact on drug interactions. THC may decrease concentrations of
clozapine, duloxetine, naproxen, cyclobenzaprine, olanzapine, haloperidol, and chlorpromazine.
CBD may increase concentrations of macrolides, calcium channel blockers, benzodiazepines,
cyclosporine, sildenafil, antihistamines, haloperidol, and antiretrovirals. CBD may increase SSRI
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concentrations, tricyclic antidepressants, antipsychotics, beta-blockers and opioids (FughBerman et al., 2020). The implications of cannabis increasing or decreasing medication
concentration can potentially disturb the effectiveness of the medication. In particular,
individuals prescribed medical marijuana for depression should be screened for potential
medication interactions to determine whether the benefits outweigh the risks.
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CHAPTER V: DISCUSSION
The purpose of this review was to gain an understanding of the current research on
medical marijuana use for PTSD, anxiety disorders, and depressive disorders in an attempt to
determine best practices in prescribing medical marijuana. Medical marijuana continues to be a
multilayered issue due to various legal implications from state to state, discrepancies in research
on effectiveness, lack of clarity in types of medical marijuana best suited for mental health
disorders, and health-related concerns. Marijuana is still considered a schedule I drug via the
Controlled Substance Act (Hudak, 2016; Drug scheduling, 2019). Therefore, certain professions
will not be able to obtain a medical marijuana card and remain employed. Marijuana laws vary
from state to state, and several states have both medical and recreational marijuana still classified
as illegal (“Map of marijuana legality by state,” 2021). The implications are that even though
medical marijuana can be an effective treatment, many Americans do not have the option to
access marijuana treatment.
There are discrepancies in the research for the addiction potential when using nabilone
due to some reported euphoric experiences due to consuming nabilone. There is considerably
more research that indicated that nabilone has been considered low in abuse potential (Clark et
al., 2005; Gourlay, 2005), and doses from the range of 1.0 mg to 5.0 mg do not have a significant
impact on altering mood states (Glass et al., 1980). Conversely, nabilone has been suggestive of
having abuse potential for individuals with substance abuse history (Fugh-Berman et al., 2020).
Therefore, substance abuse history should be considered when prescribing medical marijuana in
the THC form because the potential for cannabis abuse. Alternatively, CBD does not contain
THC and does not possess any euphoric qualities. CBD use did not show any indictors for abuse

67
potential (Bykov, 2021). CBD may be a safer alternative for individuals with treatment abuse
history and may decrease the chance of substance abuse or misuse.
Medical marijuana treatment for PTSD appeared to show promising results for the THC
extract nabilone and CBD. Additionally, one of the defining characteristics for many individuals
with PTSD is reexperiencing traumatic events. Current research suggests that CBD may increase
the consolidation of extinction learning and could reduce the impact and intensity of
reexperiencing traumatic events and potentially reduce the impact of associated stimuli that
induce traumatic memories and flashbacks. Additional research is needed to understand whether
CBD effectively increases the consolidation of extinction learning in PTSD specifically. CBD
has also been shown to reduce PTSD-related nightmares. The effective dosage for CBD is still in
question, but research has found a potential effective range. Although the dosage for effective
symptom reduction for PTSD in both THC and CBD does not appear to be fully explored, there
are general guidelines for the quantity and frequency with which these marijuana products
should be used. Flower form of medical marijuana also has limited research. Although the
current research did not include dosage (LaFrance et al., 2020), one study concluded that the
higher number of puffs of marijuana yielded greater symptom relief for PTSD. However, it is
unclear what the different potencies are between the various strains of marijuana used, and how
much marijuana (puffs) provided the maximum benefit. Also, it is unclear at what number of
puffs does the increase in symptom relief end and additional marijuana use stops providing
additional symptom relief. LaFrance et al. (2020) also noted that there were no significant
differences in PTSD symptom reduction when comparing CBD versus THC, but the dosage was
not disclosed and therefore cannot be specified based on the current research. Nabilone use has
shown improvement in PTSD symptoms including improved sleep quality and reduction in
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nightmares and a range of effective doses has been determined in several research studies.
(Cameron et al.; Roitman et al., 2014; Frazer, 2009). However, it is unclear if the dose and type
of medical marijuana (CBD or THC) is being conveyed to the actual individuals being prescribed
medical marijuana for PTSD. It may be important for medical marijuana prescribers and medical
marijuana dispensaries to inform patients that nabilone in this dose range has been found to have
an improvement on sleep related symptoms of PTSD. At the same time providing a dose range of
nabilone as a treatment for PTSD may be inaccurate due to the limited research available and
small sample sizes of participants used in research to confirm these findings.
The research for medical marijuana use to treat symptoms of anxiety disorders has shown
reduction in anxiety symptoms. The research on CBD use for anxiety disorders also appeared to
show indicators of effective symptoms reduction. However, the research does not have
consistency in identifying the effective dose of CBD that reduces anxiety symptoms. It is also
unclear of what the effective dose are for reducing anxiety symptoms in regard to individuals’
gender, age, disorder, and physical characteristics. CBD has shown significant results in reducing
social anxiety disorder (SAD) at two different doses: 400 mg (Crippa et al., 2011) and 600 mg
(Bergamaschi et al., 2011). However, due to the limited research and small sample sizes within
the research, it is difficult to confirm the effective dose for SAD symptom reduction. The
research available on other anxiety disorders that are treated with CBD or medical marijuana is
scarce. The generalizability of what the effective CBD dose is for treating various anxiety
disorders is not well researched and remains uncertain. Research on THC has shown a reduction
in self-reported anxiety symptoms (Feingold et al., 2017; LaFrance et al., 2020), but there is
limited research available that focuses on THC based medical marijuana use as a treatment for
anxiety disorders. Therefore, additional research is needed to understand what dose of THC
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based medical marijuana is effective for decreasing anxiety symptoms. Nonmedical marijuana
use in the flower form that is typically smoked appeared to have indicators of worsening PTSD
symptoms. Starting marijuana use after psychological treatment for PTSD may also contribute to
worsening of PTSD symptoms and may decrease the effectiveness of PTSD treatment.
Marijuana use has also shown higher levels of PTSD symptoms and having a positive correlation
with the higher amounts of marijuana use increases PTSD symptoms. The research suggests that
non-medical use can exacerbate PTSD symptoms and appear to have worse outcomes for
individuals with cannabis use disorder (Bon-Miller et al., 2013). Non-medical marijuana contains
potential issues for physicians prescribing medical marijuana. Individuals who use non-medical
marijuana not only may be worsening their symptoms, but they potentially increase the chances
for cognitive disturbances and impaired neuronal placidity (Abizaid et al., 2019). Prior to
prescribing medical marijuana, prescribers can utilize drug screenings to test for non-medical
marijuana use. By testing for non-medical marijuana use, prescribers can limit the number of
individuals with cannabis use disorder attempting to gain access to medical marijuana and
provide education on the benefits of utilizing CBD over THC based medical marijuana
treatments.
Research on THC is limited but has shown a reduction in acutely reducing anxiety.
Indica strains of marijuana typically have higher CBD levels and lower THC levels and have
been shown to have a calming effect, which may be of significant benefit for treating anxiety
disorders. Until there is additional research, CBD or indica strains of marijuana is the most
judicious recommendation to provide relief for anxiety in the absence of euphoria and with low
abuse potential. Marijuana use has been shown to be associated with significant levels of anxiety
in adolescents (Rusby et al., 2019) and may be a risk factor for prescribers and clinicians to
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consider when treating an adolescent. For example, a question that has not been addressed is as
follows: Is marijuana use increasing anxiety in adolescents or are adolescents who experience
anxiety more likely to engage in marijuana use? The research does not answer this question and
the results are correlational due to the research design. The legal and ethical issues may hinder
medical marijuana research with minors.
Research on medical marijuana and marijuana use in depression has many discrepancies
in the available research. Research utilizing mice and rats may help gain insight into medical
marijuana’s impact on depression, but the challenge is applying the research to humans. Medical
marijuana has been shown to improve and worsen depressive symptoms (Round et al., 2020;
Denson & Earleywine, 2006). The research that focuses on medical marijuana effective dosage
for treating depression is non-existent. Medical marijuana prescribers cannot adequately inform
their patients of the effective dose to treat depression because the information is not readily
available. It raises the question whether medical marijuana should be prescribed for depression
based on the limited data that supports its efficacy and the effective dose based on age, gender,
weight, and height.
Limitations of Current Research
Because medical marijuana is still considered illegal at the federal level, and several
states also deem medical marijuana use illegal. Researchers have additional barriers to overcome
to get approved for research. The National Institute on Drug abuse controls marijuana utilized for
research, which only allows federally authorized strains of marijuana. Researchers must gain
approval from the FDA, apply to the National Institute of Drug Abuse, and obtain a license from
the DEA to conduct the study (Anderson, 2017). The goal of these entities is to weigh the
cost/benefit of conducting medical marijuana research. The limited amount of research is partly
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due to these strict restrictions on marijuana use in studies. Researchers are at a disadvantage
when trying to focus on medical marijuana as a treatment for mental health disorders. The
alarming aspect is that medical marijuana is being prescribed for mental health disorders such as
depression, and the available research and information conflicts and does not provide definitive
answers concerning whether medical marijuana is an appropriate treatment. Other studies that
utilize surveys or record reviews lack the ability to effectively study medical marijuana treatment
or to confirm their research findings for several reasons including reliability of data and
managing research design as stated below.
There is a major disparity in research designs in studies on medical marijuana. The
research on medical marijuana lacks double-blind, randomized controlled studies. The research
that does incorporate randomized controlled studies focuses primarily on CBD. While CBD has
shown positive results in reducing PTSD, anxiety, and depressive symptoms, research is scarce.
Other designs utilized in studies consist of open-label studies, prospective trials, case studies,
retrospective chart reviews, and retrospective longitudinal observational studies. There is limited
consistency among the available research in the designs, making conclusions difficult to confirm
across the available research.
Another limitation of discussion is the wide inconsistency in how medical marijuana
treatment efficacy is measured. Studies may include various self-report measures, clinical
interpretations, and monitoring vitals, and imaging such as MRIs. Due to the lack of consistency
in how medical marijuana’s success in treating mental health disorders is measured, it is
challenging to draw conclusions from standalone research. Research also lacked consistency
between marijuana use, marijuana abuse, medical marijuana (flower form), medical THC
extracts, and medical CBD extracts. Therefore, conclusions can only be considered
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circumstantial and require additional uniform studies to help gain additional information on
which form of marijuana is advantageous for various mental health disorders. Finally, studies
suffer from a lack of generalizability due to small samples, predominately male participants, and
other limited demographic information.
Recommendations for Future Research
The challenges of the legal process will continue to be a barrier for medical marijuana
researchers unless federal laws change the schedule I narcotic status in the Controlled Substance
Act. Recommendations for research are to increase the amount of randomized double-blind
placebo-controlled studies to help reduce confounding variables and gain a clearer understanding
of medical marijuana’s impact on mental health treatment. Future studies should attempt to
collect clearly defined demographics, increase sample sizes in research conducted on medical
marijuana, attempt to find consistency in how mental health disorders are measured and
diagnosed, and identify optimal medical marijuana dosage based on gender, height, weight, and
age. Future research should focus on cannabis as a monotherapy compared to therapeutic and
pharmacological treatment. Longitudinal research is recommended to investigate if continued
medical marijuana use is needed to sustain symptom reduction or if medical marijuana use will
be needed to achieve symptom relief from mental health disorders. Finally, incorporating
research that focuses on improvement of quality of life and not only symptom reduction will be
beneficial. There are limited studies that focus on the impact medical marijuana has on
individuals treating their mental health disorders with medical marijuana.
Conclusion
Overall, medical marijuana appeared to have a therapeutic benefit for treating mental
health disorders. CBD has shown to reduce PTSD related nightmares and hyperarousal while
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also improving sleep quality. The research also suggested that CBD may promote the
consolidation of extinction learning, which would be a major breakthrough discovery if
confirmed. If CBD does assist in extinction learning, individuals who experience PTSD may
have an additional tool to help disrupt the connection between the traumatic event and the
lingering traumatic responses. Synthetic THC such as nabilone has also shown to reduce
nightmares and improve sleep quality for individuals with PTSD. Anxiety disorders also have
shown symptoms reduction with the use of both CBD and THC forms of medical marijuana.
CBD appeared to have an anxiolytic effect that can be beneficial for individuals who struggle
with managing their anxiety symptoms. As stated, THC has shown a reduction in hyperarousal,
which may assist in the reduction of physiological symptoms association with anxiety. Medical
marijuana has shown to have an acute reduction in PTSD and anxiety symptoms but does not
appear to improve or eliminate these disorders over time. Medical marijuana users may develop
a dependency on medical marijuana in order to manage their symptoms. If medical marijuana
provides symptom relief for PTSD and anxiety disorder, but does not improve these disorders
over time, does medical marijuana treatment potentially inhibit the improvement from
psychotherapy or medication management? Due to limited research, it is not yet known if
medical marijuana is more effective than psychotherapy and medication management.
Additionally, THC forms of medical marijuana may increase the chances of abuse for individuals
with a history of substance abuse. Based on the available research, treating depression with
medical marijuana had inconsistent results. Medical marijuana may worsen depressive symptoms
and may exacerbate psychosis.
Clinical psychologists, therapists, and social workers can assist in monitoring their clients
who are treated with medical marijuana. Clinicians can assist their clients by tracking any
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behavioral or emotional changes during the client’s medical marijuana treatment. If the mental
health symptoms worsen with the use of medical marijuana, clinicians can assist their clients in
relaying this information to their medical marijuana prescribers to determine if a medication
change is needed. Major warning signs include suicidal ideation, worsening depression, increase
in anxiety or PTSD related symptoms, and reported or observed hallucinations or delusions.
Marijuana has been illegal in the United States for many years and not every clinician may agree
in medical marijuana treatment. It is important for clinicians to manage their own personal views
on medical marijuana to not inhibit or promote the use of medical marijuana. Instead, clinicians
can provide psychoeducation on the benefits and risks associated with treating mental health
disorders with medical marijuana.
The question of who should be prescribed medical marijuana is not currently clear. Adult
males with PTSD and no history of substance use appear to have PTSD symptoms reduction
with medical marijuana use. Woman may also benefit from medical marijuana use, although, the
majority of the research focuses on male participants. Anxiety disorder also appear to show
reduction in symptoms when treated by medical marijuana. Research is promising in that there
may be benefits for some individuals yet there also may be potential harm in others. Medical
marijuana is likely here to stay and thus there is a strong need for continued and expanded
studies to insure the greatest benefits for all.
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